HTLV-1	B-protein
p12	I-protein
(	I-protein
I	I-protein
)	I-protein
protein	I-protein
enhances	O
STAT5	O
activation	O
and	O
decreases	O
the	O
interleukin-2	B-protein
requirement	O
for	O
proliferation	O
of	O
primary	B-cell_type
human	I-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

The	O
p12	B-protein
(	I-protein
I	I-protein
)	I-protein
protein	I-protein
,	O
encoded	O
by	O
the	O
pX	B-DNA
open	I-DNA
reading	I-DNA
frame	I-DNA
I	I-DNA
of	O
the	O
human	O
T-lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
,	O
is	O
a	O
hydrophobic	B-protein
protein	I-protein
that	O
localizes	O
to	O
the	O
endoplasmic	O
reticulum	O
and	O
the	O
Golgi	O
.	O

Although	O
p12	B-protein
(	I-protein
I	I-protein
)	I-protein
contains	O
4	O
minimal	O
proline-rich	O
,	O
src	B-protein
homology	I-protein
3-binding	I-protein
motifs	I-protein
(	O
PXXP	B-protein
)	O
,	O
a	O
characteristic	O
commonly	O
found	O
in	O
proteins	O
involved	O
in	O
signaling	O
pathways	O
,	O
it	O
has	O
not	O
been	O
known	O
whether	O
p12	B-protein
(	I-protein
I	I-protein
)	I-protein
has	O
a	O
role	O
in	O
modulating	O
intracellular	O
signaling	O
pathways	O
.	O

This	O
study	O
demonstrated	O
that	O
p12	B-protein
(	I-protein
I	I-protein
)	I-protein
binds	O
to	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
interleukin-2	B-protein
receptor	I-protein
(	I-protein
IL-2R	I-protein
)	I-protein
beta	I-protein
chain	I-protein
that	O
is	O
involved	O
in	O
the	O
recruitment	O
of	O
the	O
Jak1	B-protein
and	I-protein
Jak3	I-protein
kinases	I-protein
.	O

As	O
a	O
result	O
of	O
this	O
interaction	O
,	O
p12	B-protein
(	I-protein
I	I-protein
)	I-protein
increases	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
5	I-protein
(	O
STAT5	B-protein
)	O
DNA	O
binding	O
and	O
transcriptional	O
activity	O
and	O
this	O
effect	O
depends	O
on	O
the	O
presence	O
of	O
both	O
IL-2R	B-protein
beta	I-protein
and	I-protein
gamma	I-protein
(	I-protein
c	I-protein
)	I-protein
chains	I-protein
and	O
Jak3	B-protein
.	O

Transduction	O
of	O
primary	B-cell_line
human	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
mononuclear	I-cell_line
cells	I-cell_line
(	O
PBMCs	B-cell_type
)	O
with	O
a	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1-based	I-DNA
retroviral	I-DNA
vector	I-DNA
expressing	O
p12	B-protein
(	I-protein
I	I-protein
)	I-protein
also	O
resulted	O
in	O
increased	O
STAT5	B-protein
phosphorylation	O
and	O
DNA	O
binding	O
.	O

However	O
,	O
p12	B-protein
(	I-protein
I	I-protein
)	I-protein
could	O
increase	O
proliferation	O
of	O
human	B-cell_type
PBMCs	I-cell_type
only	O
after	O
stimulation	O
of	O
T-cell	B-protein
receptors	I-protein
by	O
treatment	O
of	O
cells	O
with	O
low	O
concentrations	O
of	O
alphaCD3	B-protein
and	I-protein
alphaCD28	I-protein
antibodies	I-protein
.	O

In	O
addition	O
,	O
the	O
proliferative	O
advantage	O
of	O
p12	B-cell_type
(	I-cell_type
I	I-cell_type
)	I-cell_type
-transduced	I-cell_type
PBMCs	I-cell_type
was	O
evident	O
mainly	O
at	O
low	O
concentrations	O
of	O
IL-2	B-protein
.	O

Together	O
,	O
these	O
data	O
indicate	O
that	O
p12	B-protein
(	I-protein
I	I-protein
)	I-protein
may	O
confer	O
a	O
proliferative	O
advantage	O
on	O
HTLV-1-infected	B-cell_type
cells	I-cell_type
in	O
the	O
presence	O
of	O
suboptimal	O
antigen	O
stimulation	O
and	O
that	O
this	O
event	O
may	O
account	O
for	O
the	O
clonal	O
proliferation	O
of	O
infected	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
vivo	O
.	O

(	O
Blood.	O
2001	O
;	O
98	O
:	O
823-829	O
)	O

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

NEOPLASIA	NULL
HTLV-1	NULL
p12	NULL
!	NULL

protein	NULL
enhances	NULL
STATS	NULL
activation	NULL
and	NULL
decreases	NULL
the	NULL
interleukin-2	NULL
requirement	NULL
for	NULL
proliferation	NULL
of	NULL
primary	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
Christophe	NULL
Nicot	NULL
,	NULL
James	NULL
C.	NULL
Mulloy	NULL
,	NULL
Maria	NULL
G.	NULL
Ferrari	NULL
,	NULL
Julie	NULL
M.	NULL
Johnson	NULL
,	NULL
Kaisong	NULL
Fu	NULL
,	NULL
Risaku	NULL
Fukumoto	NULL
,	NULL
Raffaella	NULL
Trovato	NULL
,	NULL
Jake	NULL
Fullen	NULL
,	NULL
Warren	NULL
J.	NULL
Leonard	NULL
,	NULL
and	NULL
Genoveffa	NULL
Franchini	NULL
The	NULL
p12	NULL
!	NULL

protein	NULL
,	NULL
encoded	NULL
by	NULL
the	NULL
pX	NULL
open	NULL
reading	NULL
frame	NULL
|	NULL
of	NULL
the	NULL
human	NULL
T-lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HTLV-1	NULL
)	NULL
,	NULL
is	NULL
a	NULL
hydrophobic	NULL
protein	NULL
that	NULL
localizes	NULL
to	NULL
the	NULL
endoplasmic	NULL
reticulum	NULL
and	NULL
the	NULL
Golgi	NULL
.	NULL

Although	NULL
p12	NULL
!	NULL

contains	NULL
4	NULL
minimal	NULL
proline-rich	NULL
,	NULL
src	NULL
homology	NULL
3-binding	NULL
motifs	NULL
(	NULL
PXXP	NULL
)	NULL
,	NULL
a	NULL
characteristic	NULL
commonly	NULL
found	NULL
in	NULL
proteins	NULL
involved	NULL
in	NULL
signaling	NULL
pathways	NULL
,	NULL
it	NULL
has	NULL
not	NULL
been	NULL
known	NULL
whether	NULL
p12	NULL
'	NULL
has	NULL
a	NULL
role	NULL
in	NULL
modulating	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
.	NULL

This	NULL
study	NULL
demonstrated	NULL
that	NULL
p12	NULL
!	NULL

binds	NULL
to	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
the	NULL
interleukin-2	NULL
receptor	NULL
(	NULL
IL-2R	NULL
)	NULL
B	NULL
chain	NULL
that	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
recruitment	NULL
of	NULL
the	NULL
Jak1	NULL
and	NULL
Jak3	NULL
kinases	NULL
.	NULL

As	NULL
a	NULL
result	NULL
of	NULL
this	NULL
interaction	NULL
,	NULL
p12	NULL
!	NULL

increases	NULL
signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
5	NULL
(	NULL
STATS	NULL
)	NULL
DNA	NULL
binding	NULL
and	NULL
transcriptional	NULL
activity	NULL
and	NULL
this	NULL
effect	NULL
depends	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
both	NULL
IL-2R	NULL
B	NULL
and	NULL
y	NULL
,	NULL
chains	NULL
and	NULL
Jak3	NULL
.	NULL

Transduction	NULL
of	NULL
primary	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
with	NULL
a	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1-based	NULL
retroviral	NULL
vector	NULL
expressing	NULL
p12	NULL
!	NULL

also	NULL
resulted	NULL
in	NULL
increased	NULL
STATS	NULL
phosphorylation	NULL
and	NULL
DNA	NULL
binding	NULL
.	NULL

However	NULL
,	NULL
p12	NULL
!	NULL

could	NULL
increase	NULL
proliferation	NULL
of	NULL
human	NULL
PBMCs	NULL
only	NULL
after	NULL
stimulation	NULL
of	NULL
T-cell	NULL
receptors	NULL
by	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
low	NULL
concentrations	NULL
of	NULL
«	NULL
CD3	NULL
and	NULL
«	NULL
CD28	NULL
antibodies	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
proliferative	NULL
advantage	NULL
of	NULL
p12-transduced	NULL
PBMCs	NULL
was	NULL
evident	NULL
mainly	NULL
at	NULL
low	NULL
concentrations	NULL
of	NULL
IL-2	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
p12	NULL
!	NULL

may	NULL
confer	NULL
a	NULL
proliferative	NULL
advantage	NULL
on	NULL
HTLV-1-infected	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
suboptimal	NULL
antigen	NULL
stimulation	NULL
and	NULL
that	NULL
this	NULL
event	NULL
may	NULL
account	NULL
for	NULL
the	NULL
clonal	NULL
proliferation	NULL
of	NULL
infected	NULL
T	NULL
cells	NULL
in	NULL
vivo	NULL
.	NULL

(	NULL
Blood	NULL
.	NULL

2001	NULL
;	NULL
98:823-829	NULL
)	NULL
©2001	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
Introduction	NULL
Human	NULL
T-lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HTLV-1	NULL
)	NULL
causes	NULL
adult	NULL
T-cell	NULL
leukemia/lymphoma	NULL
(	NULL
ATLL	NULL
)	NULL
,	NULL
!	NULL

and	NULL
its	NULL
genome	NULL
carries	NULL
genetic	NULL
information	NULL
for	NULL
the	NULL
structural	NULL
and	NULL
enzymatic	NULL
proteins	NULL
,	NULL
the	NULL
regulatory	NULL
proteins	NULL
Tax	NULL
and	NULL
Rex	NULL
,	NULL
and	NULL
other	NULL
open	NULL
reading	NULL
frames	NULL
(	NULL
orfs	NULL
)	NULL
encoding	NULL
small	NULL
proteins	NULL
with	NULL
largely	NULL
unknown	NULL
functions	NULL
.	NULL
``	NULL

HTLV-1	NULL
infects	NULL
and	NULL
immortalizes	NULL
primary	NULL
human	NULL
T	NULL
cells	NULL
in	NULL
vitro	NULL
,	NULL
and	NULL
after	NULL
several	NULL
months	NULL
,	NULL
these	NULL
cells	NULL
acquire	NULL
the	NULL
ability	NULL
to	NULL
grow	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
.	NULL
'	NULL

The	NULL
switch	NULL
to	NULL
IL-2	NULL
independence	NULL
correlates	NULL
in	NULL
most	NULL
cases	NULL
with	NULL
acquisition	NULL
of	NULL
a	NULL
constitutive	NULL
activation	NULL
of	NULL
the	NULL
Jak/signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
(	NULL
STAT	NULL
)	NULL
pathway**	NULL
and	NULL
decreased	NULL
expression	NULL
of	NULL
the	NULL
src	NULL
homology	NULL
2-contain-ing	NULL
tyrosine	NULL
phosphatase	NULL
1	NULL
protein	NULL
,	NULL
``	NULL
which	NULL
regulates	NULL
signaling	NULL
from	NULL
several	NULL
hematopoietic	NULL
surface	NULL
receptors	NULL
.	NULL

!	NULL
``	NULL

HTLV-1	NULL
also	NULL
confers	NULL
longevity	NULL
on	NULL
T	NULL
cells	NULL
in	NULL
vivo	NULL
,	NULL
since	NULL
expansion	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
identical	NULL
integrations	NULL
for	NULL
HTLV-1	NULL
can	NULL
be	NULL
found	NULL
at	NULL
several-year	NULL
intervals	NULL
in	NULL
the	NULL
same	NULL
infected	NULL
individuals	NULL
.	NULL
``	NULL

These	NULL
findings	NULL
raise	NULL
the	NULL
question	NULL
of	NULL
how	NULL
CD4*	NULL
T	NULL
cells	NULL
carrying	NULL
the	NULL
HTLV-1	NULL
provirus	NULL
can	NULL
expand	NULL
and	NULL
survive	NULL
for	NULL
a	NULL
long	NULL
time	NULL
in	NULL
vivo	NULL
.	NULL

The	NULL
HTLV-1	NULL
p12	NULL
``	NULL
protein	NULL
,	NULL
a	NULL
hydrophobic	NULL
protein	NULL
resident	NULL
in	NULL
the	NULL
endoplasmic	NULL
reticulum	NULL
(	NULL
ER	NULL
)	NULL
and	NULL
Golgi®®	NULL
that	NULL
is	NULL
encoded	NULL
by	NULL
the	NULL
3	NULL
'	NULL
end	NULL
orf	NULL
I	NULL
of	NULL
the	NULL
viral	NULL
genome	NULL
,	NULL
``	NULL
forms	NULL
dimers	NULL
,	NULL
``	NULL
has	NULL
weak	NULL
oncogenic	NULL
properties	NULL
,	NULL
and	NULL
binds	NULL
to	NULL
the	NULL
p16	NULL
subunit	NULL
of	NULL
the	NULL
vacuolar	NULL
hydrogen	NULL
adenosine	NULL
diphosphatase	NULL
(	NULL
H*	NULL
ATPase	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
p12	NULL
``	NULL
in	NULL
infected	NULL
cells	NULL
is	NULL
suggested	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
transcripts	NULL
in	NULL
cultured	NULL
>	NULL
``	NULL
``	NULL
and	NULL
ex	NULL
vivo	NULL
cells	NULL
from	NULL
individuals	NULL
infected	NULL
with	NULL
HTLV-1	NULL
.	NULL
``	NULL

The	NULL
orf	NULL
I	NULL
is	NULL
likely	NULL
expressed	NULL
in	NULL
vivo	NULL
because	NULL
antibodies	NULL
(	NULL
Abs	NULL
)	NULL
and	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
to	NULL
peptides	NULL
from	NULL
the	NULL
orf	NULL
I	NULL
protein	NULL
have	NULL
been	NULL
detected	NULL
.	NULL
'	NULL

''	NULL
``	NULL
``	NULL
Importantly	NULL
,	NULL
ablation	NULL
of	NULL
the	NULL
splice	NULL
acceptor	NULL
site	NULL
for	NULL
the	NULL
singly	NULL
spliced	NULL
p12	NULL
!	NULL

messenger	NULL
RNA	NULL
from	NULL
a	NULL
molecular	NULL
clone	NULL
of	NULL
HTLV-1	NULL
impaired	NULL
viral	NULL
infectivity	NULL
in	NULL
a	NULL
rabbit	NULL
model	NULL
in	NULL
This	NULL
may	NULL
be	NULL
partly	NULL
related	NULL
to	NULL
the	NULL
finding	NULL
that	NULL
p12	NULL
``	NULL
interferes	NULL
with	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
I	NULL
(	NULL
MHC	NULL
I	NULL
)	NULL
heavy-chain	NULL
trafficking	NULL
and	NULL
may	NULL
facilitate	NULL
escape	NULL
of	NULL
HTLV-1-infected	NULL
cells	NULL
from	NULL
the	NULL
host	NULL
's	NULL
immune	NULL
surveillance	NULL
.	NULL
``	NULL

We	NULL
previously	NULL
reported	NULL
that	NULL
p12	NULL
!	NULL

also	NULL
binds	NULL
the	NULL
IL-2	NULL
receptor	NULL
(	NULL
IL-2R	NULL
)	NULL
B	NULL
and	NULL
y	NULL
,	NULL
chains	NULL
and	NULL
affects	NULL
their	NULL
expression	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
.	NULL

!	NULL
``	NULL

IL-2	NULL
is	NULL
an	NULL
essential	NULL
cytokine	NULL
for	NULL
the	NULL
growth	NULL
and	NULL
survival	NULL
of	NULL
T	NULL
cells	NULL
.	NULL
``	NULL

''	NULL
Binding	NULL
of	NULL
IL-2	NULL
to	NULL
the	NULL
IL-2R	NULL
B	NULL
and	NULL
y	NULL
,	NULL
,	NULL
chains	NULL
results	NULL
in	NULL
activation	NULL
and	NULL
recruitment	NULL
of	NULL
Jak1	NULL
and	NULL
Jak3	NULL
and	NULL
phosphorylation	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
STAT5a	NULL
and	NULL
STAT5b	NULL
.	NULL

STAT	NULL
proteins	NULL
have	NULL
been	NULL
found	NULL
to	NULL
be	NULL
activated	NULL
with	NULL
a	NULL
high	NULL
frequency	NULL
in	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
human	NULL
cancers	NULL
,	NULL
``	NULL
and	NULL
STAT1	NULL
,	NULL
STAT3	NULL
,	NULL
and	NULL
STAT5	NULL
were	NULL
shown	NULL
to	NULL
be	NULL
activated	NULL
in	NULL
70	NULL
%	NULL
of	NULL
ATLL	NULL
primary	NULL
cells	NULL
.	NULL
``	NULL

In	NULL
fact	NULL
,	NULL
there	NULL
is	NULL
good	NULL
evidence	NULL
that	NULL
constitutively	NULL
activated	NULL
STAT	NULL
signaling	NULL
participates	NULL
in	NULL
oncogenesis	NULL
by	NULL
simultaneously	NULL
promoting	NULL
cell	NULL
proliferation	NULL
and	NULL
preventing	NULL
apoptosis	NULL
.	NULL
``	NULL

Because	NULL
p12	NULL
``	NULL
interacts	NULL
with	NULL
the	NULL
IL-2R	NULL
B	NULL
and	NULL
IL-2R	NULL
y	NULL
,	NULL
,	NULL
chains	NULL
,	NULL
we	NULL
hypothesized	NULL
that	NULL
p12	NULL
!	NULL

may	NULL
interfere	NULL
with	NULL
or	NULL
augment	NULL
signaling	NULL
From	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Basic	NULL
Research	NULL
Laboratory	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
;	NULL
and	NULL
the	NULL
National	NULL
Heart	NULL
,	NULL
Lung	NULL
,	NULL
and	NULL
Blood	NULL
Institute	NULL
,	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Immunology	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
.	NULL

Submitted	NULL
October	NULL
3	NULL
,	NULL
2000	NULL
;	NULL
accepted	NULL
March	NULL
28	NULL
,	NULL
2001	NULL
.	NULL

C.N	NULL
.	NULL

and	NULL
J.C.M	NULL
.	NULL

contributed	NULL
equally	NULL
.	NULL

BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
Reprints	NULL
:	NULL
Genoveffa	NULL
Franchini	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Basic	NULL
Research	NULL
Laboratory	NULL
,	NULL
41/0804	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20892	NULL
;	NULL
e-mail	NULL
:	NULL
veffa	NULL
@	NULL
helix.nin.gov	NULL
.	NULL

The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

Therefore	NULL
,	NULL
and	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
,	NULL
this	NULL
article	NULL
is	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

section	NULL
1734	NULL
.	NULL

©2001	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
823	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

824	NULL
_	NULL
NICOT	NULL
etal	NULL
pathways	NULL
and	NULL
contribute	NULL
to	NULL
proliferation	NULL
of	NULL
T	NULL
cells	NULL
infected	NULL
with	NULL
HTLV-1	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
found	NULL
that	NULL
p12	NULL
``	NULL
,	NULL
through	NULL
its	NULL
binding	NULL
to	NULL
the	NULL
IL-2R	NULL
B	NULL
chain	NULL
,	NULL
increased	NULL
STAT	NULL
5b	NULL
transcriptional	NULL
activation	NULL
and	NULL
simultaneously	NULL
decreased	NULL
the	NULL
T-cell	NULL
requirement	NULL
for	NULL
IL-2	NULL
for	NULL
proliferation	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Expression	NULL
plasmids	NULL
The	NULL
p12	NULL
``	NULL
complementary	NULL
DNA	NULL
tagged	NULL
with	NULL
the	NULL
AU1	NULL
or	NULL
HA1	NULL
epitopes	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
wild-type	NULL
IL-2R	NULL
B	NULL
and	NULL
IL-2R	NULL
y	NULL
,	NULL
,	NULL
chains	NULL
and	NULL
mutants	NULL
for	NULL
both	NULL
chains	NULL
,	NULL
were	NULL
cloned	NULL
in	NULL
the	NULL
pME18S	NULL
plasmid	NULL
.	NULL

IL-2R	NULL
B-chain	NULL
mutants	NULL
B33	NULL
,	NULL
Bs5p	NULL
,	NULL
AH	NULL
,	NULL
AS	NULL
,	NULL
AA	NULL
,	NULL
and	NULL
AST	NULL
were	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

The	NULL
remaining	NULL
IL-2R	NULL
B-chain	NULL
mutants	NULL
were	NULL
generated	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
using	NULL
the	NULL
AST	NULL
plasmid	NULL
and	NULL
resulted	NULL
in	NULL
deletion	NULL
of	NULL
amino	NULL
acid	NULL
residues	NULL
264	NULL
to	NULL
296	NULL
and	NULL
350	NULL
to	NULL
525	NULL
,	NULL
264	NULL
to	NULL
350	NULL
and	NULL
432	NULL
to	NULL
525	NULL
,	NULL
and	NULL
264	NULL
to	NULL
390	NULL
,	NULL
indicated	NULL
by	NULL
subscripts	NULL
in	NULL
the	NULL
following	NULL
:	NULL
AST	NULL
;	NULL
2956.350	NULL
,	NULL
AST	NULL
1350-432	NULL
,	NULL
and	NULL
AST	NULL
399-525	NULL
.	NULL

All	NULL
plasmids	NULL
were	NULL
verified	NULL
by	NULL
sequencing	NULL
.	NULL

The	NULL
BCD4B	NULL
and	NULL
the	NULL
«	NULL
af	NULL
chimeric	NULL
receptors	NULL
,	NULL
which	NULL
were	NULL
described	NULL
previously	NULL
,	NULL
``	NULL
contain	NULL
the	NULL
B	NULL
chain	NULL
in	NULL
which	NULL
the	NULL
transmembrane	NULL
region	NULL
has	NULL
been	NULL
exchanged	NULL
with	NULL
the	NULL
equivalent	NULL
region	NULL
of	NULL
the	NULL
CD4	NULL
receptor	NULL
(	NULL
BCD4B	NULL
)	NULL
or	NULL
the	NULL
extracellular	NULL
and	NULL
transmembrane	NULL
region	NULL
of	NULL
the	NULL
«	NULL
chain	NULL
has	NULL
been	NULL
joined	NULL
to	NULL
the	NULL
B-chain	NULL
cytoplasmic	NULL
portion	NULL
.	NULL

Lentiviral	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
-based	NULL
retroviral	NULL
vector	NULL
HR	NULL
'cyto-megalovirus	NULL
(	NULL
CMV	NULL
)	NULL
-Luc	NULL
,	NULL
CMV-driven	NULL
HIV	NULL
helper	NULL
virus	NULL
deleted	NULL
for	NULL
the	NULL
erv	NULL
and	NULL
nef	NULL
genes	NULL
(	NULL
pDNL6	NULL
)	NULL
,	NULL
and	NULL
the	NULL
HIV	NULL
long	NULL
terminal	NULL
repeat-vesicular	NULL
stomatitis	NULL
virus	NULL
G	NULL
(	NULL
VSV-G	NULL
)	NULL
envelope	NULL
were	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

HA-tagged	NULL
p12	NULL
!	NULL

was	NULL
amplified	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
using	NULL
Turbo	NULL
PFU	NULL
polymerase	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
,	NULL
sequenced	NULL
,	NULL
and	NULL
cloned	NULL
between	NULL
BamH1	NULL
and	NULL
Xhol	NULL
restriction	NULL
sites	NULL
(	NULL
HR'CMV	NULL
p12	NULL
``	NULL
HA	NULL
)	NULL
.	NULL

DNA	NULL
transfections	NULL
,	NULL
immunoprecipitations	NULL
,	NULL
Western	NULL
blotting	NULL
,	NULL
and	NULL
immunofluorescence	NULL
One	NULL
million	NULL
COS-7	NULL
or	NULL
1.2	NULL
X	NULL
106	NULL
293T	NULL
cells	NULL
were	NULL
plated	NULL
in	NULL
a	NULL
100-mm	NULL
dish	NULL
and	NULL
transfected	NULL
the	NULL
next	NULL
day	NULL
with	NULL
10	NULL
jpg	NULL
of	NULL
each	NULL
plasmid	NULL
by	NULL
using	NULL
the	NULL
calcium	NULL
phosphate	NULL
method	NULL
.	NULL
``	NULL

''	NULL
Cells	NULL
were	NULL
then	NULL
collected	NULL
,	NULL
washed	NULL
in	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
,	NULL
lysed	NULL
in	NULL
lysis	NULL
buffer	NULL
by	NULL
freeze-thawing	NULL
,	NULL
and	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

Abs	NULL
against	NULL
the	NULL
AU1	NULL
(	NULL
Berkeley	NULL
Antibody	NULL
,	NULL
Richmond	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
HA1l	NULL
(	NULL
12CA5	NULL
;	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
epitopes	NULL
were	NULL
used	NULL
to	NULL
immunoprecipitate	NULL
the	NULL
wild-type	NULL
p12	NULL
``	NULL
mutants	NULL
.	NULL

Monoclonal	NULL
Ab	NULL
anti-B	NULL
chain	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
,	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
was	NULL
used	NULL
to	NULL
immunoprecipitate	NULL
the	NULL
IL-2R	NULL
B	NULL
chain	NULL
in	NULL
association	NULL
with	NULL
protein	NULL
glycine	NULL
agarose	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
.	NULL

Polyclonal	NULL
rabbit	NULL
serum	NULL
was	NULL
used	NULL
to	NULL
detect	NULL
B-chain	NULL
protein	NULL
with	NULL
antirabbit	NULL
horseradish	NULL
peroxidase	NULL
conjugated	NULL
as	NULL
secondary	NULL
Ab	NULL
.	NULL

Immu-noprecipitations	NULL
were	NULL
done	NULL
in	NULL
radicimmunoprecipitation	NULL
assay	NULL
(	NULL
RIPA	NULL
)	NULL
buffer	NULL
overnight	NULL
at	NULL
4°C	NULL
by	NULL
using	NULL
2	NULL
jug/mL	NULL
Ab	NULL
.	NULL

Protein	NULL
glycine	NULL
agarose	NULL
was	NULL
then	NULL
added	NULL
.	NULL

After	NULL
an	NULL
additional	NULL
2	NULL
hours	NULL
at	NULL
4°C	NULL
,	NULL
immunocomplexes	NULL
were	NULL
washed	NULL
in	NULL
RIPA	NULL
buffer	NULL
containing	NULL
Tween	NULL
20	NULL
0.1	NULL
%	NULL
,	NULL
resolved	NULL
on	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
SDS-PAGE	NULL
)	NULL
gels	NULL
(	NULL
Novex	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
and	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
(	NULL
Hybond	NULL
;	NULL
Amersham	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Detection	NULL
was	NULL
done	NULL
with	NULL
a	NULL
chemilu-minescent	NULL
system	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Labeled	NULL
proteins	NULL
were	NULL
analyzed	NULL
in	NULL
15	NULL
%	NULL
SDS-PAGE	NULL
gel	NULL
and	NULL
visualized	NULL
on	NULL
X-Omat	NULL
film	NULL
(	NULL
Kodak	NULL
,	NULL
Rochester	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Western	NULL
blotting	NULL
for	NULL
STATS	NULL
was	NULL
done	NULL
by	NULL
using	NULL
Ab	NULL
Y694	NULL
and	NULL
Y699	NULL
(	NULL
Upstate	NULL
,	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Pseudotype	NULL
virus	NULL
production	NULL
and	NULL
concentration	NULL
The	NULL
293T	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
seeded	NULL
on	NULL
a	NULL
10-cm	NULL
dish	NULL
and	NULL
transfected	NULL
the	NULL
following	NULL
day	NULL
with	NULL
VSV-G	NULL
(	NULL
2	NULL
g	NULL
)	NULL
,	NULL
pDNL6	NULL
(	NULL
4	NULL
pug	NULL
)	NULL
,	NULL
and	NULL
HR'CMV-Luc	NULL
or	NULL
HR'CMV	NULL
p12	NULL
!	NULL

(	NULL
4	NULL
ug	NULL
)	NULL
by	NULL
using	NULL
an	NULL
Effectene	NULL
reagent	NULL
kit	NULL
(	NULL
Qiagen	NULL
,	NULL
Valencia	NULL
,	NULL
CA	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Supernatant	NULL
from	NULL
20	NULL
dishes	NULL
was	NULL
collected	NULL
every	NULL
12	NULL
hours	NULL
from	NULL
24	NULL
hours	NULL
to	NULL
72	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
cleared	NULL
of	NULL
cellular	NULL
debris	NULL
by	NULL
centrifugation	NULL
at	NULL
8000g	NULL
for	NULL
10	NULL
minutes	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
filtered	NULL
through	NULL
a	NULL
0.45	NULL
jum	NULL
filter	NULL
,	NULL
and	NULL
stored	NULL
at	NULL
BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
-80°C	NULL
.	NULL

Pseudotype	NULL
viruses	NULL
were	NULL
formed	NULL
into	NULL
pellets	NULL
by	NULL
ultracentrifugation	NULL
at	NULL
50	NULL
000g	NULL
(	NULL
28	NULL
000	NULL
rpm	NULL
with	NULL
a	NULL
SW41	NULL
rotor	NULL
)	NULL
for	NULL
1.75	NULL
hours	NULL
at	NULL
4°C	NULL
.	NULL

Virus	NULL
was	NULL
then	NULL
resuspended	NULL
in	NULL
PBS	NULL
by	NULL
means	NULL
of	NULL
a	NULL
4-hour	NULL
incubation	NULL
on	NULL
ice	NULL
,	NULL
collected	NULL
,	NULL
divided	NULL
into	NULL
aliquots	NULL
,	NULL
and	NULL
stored	NULL
at	NULL
-80°C	NULL
.	NULL

HIV	NULL
gag	NULL
p24	NULL
was	NULL
measured	NULL
by	NULL
using	NULL
an	NULL
antigen	NULL
capture	NULL
assay	NULL
(	NULL
Coulter	NULL
,	NULL
Miami	NULL
,	NULL
FL	NULL
)	NULL
.	NULL

Primary	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
were	NULL
infected	NULL
by	NULL
using	NULL
comparable	NULL
amounts	NULL
of	NULL
viral	NULL
particles	NULL
for	NULL
both	NULL
HR'CMV-Luc	NULL
and	NULL
HR'CMV	NULL
p12	NULL
.	NULL

Infectivity	NULL
and	NULL
expression	NULL
were	NULL
verified	NULL
by	NULL
immunofluorescence	NULL
and	NULL
immunoprecipitation	NULL
Western	NULL
blot	NULL
assays	NULL
.	NULL

Primary	NULL
T-cell	NULL
infection	NULL
and	NULL
proliferation	NULL
assay	NULL
Mononuclear	NULL
cells	NULL
from	NULL
peripheral	NULL
blood	NULL
of	NULL
healthy	NULL
volunteers	NULL
were	NULL
purified	NULL
by	NULL
Ficoll-Hypaque	NULL
methods	NULL
(	NULL
Hyclone	NULL
,	NULL
Logan	NULL
,	NULL
UT	NULL
)	NULL
,	NULL
washed	NULL
in	NULL
PBS	NULL
,	NULL
and	NULL
either	NULL
used	NULL
as	NULL
such	NULL
or	NULL
after	NULL
suboptimal	NULL
stimulation	NULL
obtained	NULL
by	NULL
phytohemagglutinin	NULL
(	NULL
PHA	NULL
;	NULL
1	NULL
ng/mL	NULL
)	NULL
or	NULL
CD3/CD28	NULL
(	NULL
0.5	NULL
ng/mL	NULL
)	NULL
for	NULL
24	NULL
hours	NULL
before	NULL
infection	NULL
with	NULL
HR'CMV	NULL
p12	NULL
``	NULL
or	NULL
HR'CMV-Luec	NULL
VSV	NULL
pseudotyped	NULL
viruses	NULL
.	NULL

Infected	NULL
cells	NULL
were	NULL
plated	NULL
in	NULL
duplicate	NULL
in	NULL
a	NULL
96-well	NULL
plate	NULL
(	NULL
3	NULL
X	NULL
10+	NULL
cells/well	NULL
)	NULL
in	NULL
100	NULL
L	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
20	NULL
%	NULL
fetal-calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
2.5	NULL
,	NULL
5	NULL
,	NULL
or	NULL
10	NULL
U/mL	NULL
IL-2	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
.	NULL

Cellular	NULL
proliferation	NULL
assays	NULL
were	NULL
done	NULL
on	NULL
days	NULL
2	NULL
,	NULL
3	NULL
,	NULL
4	NULL
,	NULL
and	NULL
6	NULL
after	NULL
infection	NULL
by	NULL
using	NULL
a	NULL
Colorimetric	NULL
Cell	NULL
Proliferation	NULL
Kit	NULL
II	NULL
(	NULL
Roche	NULL
Molecular	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
as	NULL
described	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

Spectrophotometric	NULL
absorbance	NULL
was	NULL
measured	NULL
with	NULL
a	NULL
mean	NULL
filter	NULL
at	NULL
492	NULL
nm	NULL
and	NULL
a	NULL
reference	NULL
filter	NULL
at	NULL
690	NULL
nm	NULL
.	NULL

SDs	NULL
were	NULL
calculated	NULL
from	NULL
values	NULL
obtained	NULL
from	NULL
2	NULL
independent	NULL
infections	NULL
of	NULL
each	NULL
donor	NULL
cell	NULL
,	NULL
and	NULL
results	NULL
were	NULL
representative	NULL
of	NULL
3	NULL
independent	NULL
experiments	NULL
done	NULL
using	NULL
cells	NULL
from	NULL
3	NULL
human	NULL
volunteers	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
PBMCs	NULL
from	NULL
healthy	NULL
volunteers	NULL
were	NULL
purified	NULL
with	NULL
the	NULL
Ficoll-Hypaque	NULL
method	NULL
,	NULL
washed	NULL
in	NULL
PBS	NULL
,	NULL
activated	NULL
with	NULL
5	NULL
g/mL	NULL
PHA	NULL
for	NULL
3	NULL
days	NULL
,	NULL
washed	NULL
again	NULL
in	NULL
PBS	NULL
,	NULL
and	NULL
cultured	NULL
for	NULL
5	NULL
days	NULL
in	NULL
RPMI	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
10	NULL
U/mL	NULL
IL-2	NULL
.	NULL

Lymphocytes	NULL
were	NULL
infected	NULL
with	NULL
HR'CMV	NULL
p12	NULL
``	NULL
or	NULL
HR'CMV-Luc	NULL
pseudotype	NULL
viruses	NULL
.	NULL

After	NULL
18	NULL
hours	NULL
,	NULL
PBMCs	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
medium	NULL
free	NULL
of	NULL
serum	NULL
and	NULL
IL-2	NULL
and	NULL
deprived	NULL
overnight	NULL
of	NULL
serum	NULL
(	NULL
0.1	NULL
%	NULL
)	NULL
and	NULL
stimulation	NULL
with	NULL
IL-2	NULL
.	NULL

The	NULL
next	NULL
day	NULL
,	NULL
infected	NULL
PBMCs	NULL
were	NULL
divided	NULL
into	NULL
6	NULL
batches	NULL
of	NULL
2	NULL
X	NULL
10°	NULL
cells	NULL
and	NULL
pulsed	NULL
with	NULL
0.1	NULL
,	NULL
1	NULL
,	NULL
10	NULL
,	NULL
100	NULL
,	NULL
or	NULL
1000	NULL
U/mL	NULL
IL-2	NULL
for	NULL
10	NULL
minutes	NULL
at	NULL
37°C	NULL
.	NULL

Unstimulated	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
controls	NULL
for	NULL
basal	NULL
levels	NULL
of	NULL
STATS	NULL
activation	NULL
.	NULL

Cells	NULL
were	NULL
collected	NULL
by	NULL
centrifugation	NULL
and	NULL
washed	NULL
and	NULL
lysed	NULL
in	NULL
20	NULL
pL	NULL
lysis	NULL
buffer	NULL
.	NULL
``	NULL

Binding	NULL
reactions	NULL
were	NULL
done	NULL
with	NULL
2	NULL
ug	NULL
protein	NULL
extract	NULL
,	NULL
as	NULL
previously	NULL
reported	NULL
,	NULL
``	NULL
with	NULL
an	NULL
increase	NULL
in	NULL
incubation	NULL
time	NULL
from	NULL
30	NULL
minutes	NULL
to	NULL
1	NULL
hour	NULL
.	NULL

STATS	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
measured	NULL
by	NULL
using	NULL
phosphorus	NULL
32	NULL
(	NULL
@	NULL
P	NULL
)	NULL
-labeled	NULL
B-casein	NULL
y-interferon	NULL
activated	NULL
sequence	NULL
(	NULL
GAS	NULL
)	NULL
elements	NULL
.	NULL

The	NULL
DNA-protein	NULL
complexes	NULL
were	NULL
separated	NULL
on	NULL
prerun	NULL
5	NULL
%	NULL
native	NULL
polyacrylamide	NULL
gels	NULL
in	NULL
0.5	NULL
X	NULL
Tris	NULL
borate	NULL
EDTA	NULL
buffer	NULL
at	NULL
200	NULL
V	NULL
for	NULL
2	NULL
hours	NULL
.	NULL

Gels	NULL
were	NULL
dried	NULL
and	NULL
exposed	NULL
to	NULL
x-ray	NULL
film	NULL
at	NULL
-80°C	NULL
.	NULL

Gel-shift	NULL
analysis	NULL
using	NULL
the	NULL
B-casein	NULL
GAS	NULL
element	NULL
was	NULL
done	NULL
as	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

COS-7	NULL
cells	NULL
were	NULL
transfected	NULL
and	NULL
pulsed	NULL
with	NULL
the	NULL
selected	NULL
amounts	NULL
of	NULL
IL-2	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
made	NULL
,	NULL
and	NULL
10	NULL
jug	NULL
of	NULL
nuclear	NULL
extracts	NULL
were	NULL
incubated	NULL
with	NULL
20	NULL
000	NULL
cpm	NULL
3°P-labeled	NULL
B-casein	NULL
GAS	NULL
element	NULL
and	NULL
run	NULL
on	NULL
5	NULL
%	NULL
native	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

Results	NULL
The	NULL
20-amino	NULL
acid	NULL
stretch	NULL
of	NULL
IL-2R	NULL
B	NULL
involved	NULL
in	NULL
Jaki	NULL
and	NULL
Jak3	NULL
recruitment	NULL
binds	NULL
p12	NULL
To	NULL
identify	NULL
the	NULL
site	NULL
of	NULL
p12	NULL
!	NULL

interaction	NULL
within	NULL
the	NULL
B	NULL
chain	NULL
,	NULL
the	NULL
BCD4f	NULL
and	NULL
«	NULL
«	NULL
fB	NULL
chimeric	NULL
molecules	NULL
were	NULL
used	NULL
.	NULL
``	NULL

Both	NULL
chimeric	NULL
molecules	NULL
coprecipitated	NULL
with	NULL
p12	NULL
'	NULL
,	NULL
indicating	NULL
that	NULL
neither	NULL
the	NULL
transmembrane	NULL
nor	NULL
the	NULL
extracellular	NULL
domains	NULL
of	NULL
B	NULL
were	NULL
the	NULL
primary	NULL
sites	NULL
of	NULL
p12	NULL
!	NULL

interaction	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Mutants	NULL
lacking	NULL
different	NULL
regions	NULL
of	NULL
the	NULL
B-chain	NULL
cytoplasmic	NULL
domain	NULL
were	NULL
coexpressed	NULL
with	NULL
p12	NULL
,	NULL
and	NULL
the	NULL
cell	NULL
lysate	NULL
was	NULL
divided	NULL
in	NULL
half	NULL
and	NULL
subjected	NULL
to	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
immunoprecipitation	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
with	NULL
Ab	NULL
to	NULL
the	NULL
receptor	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
;	NULL
goat	NULL
antiserum	NULL
against	NULL
human	NULL
IL-2R	NULL
B	NULL
[	NULL
RDB	NULL
]	NULL
)	NULL
and	NULL
to	NULL
p12	NULL
!	NULL

(	NULL
«	NULL
eHA1	NULL
)	NULL
(	NULL
Figure	NULL
1	NULL
)	NULL
.	NULL

The	NULL
BAST	NULL
mutant	NULL
lacking	NULL
most	NULL
of	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
(	NULL
A267	NULL
)	NULL
failed	NULL
to	NULL
bind	NULL
p12	NULL
``	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
bottom	NULL
panel	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
B33	NULL
,	NULL
mutant	NULL
also	NULL
failed	NULL
to	NULL
bind	NULL
p12	NULL
,	NULL
the	NULL
Bsp	NULL
mutant	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
did	NULL
bind	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
region	NULL
encompassing	NULL
amino	NULL
acids	NULL
330	NULL
to	NULL
350	NULL
of	NULL
the	NULL
receptor	NULL
was	NULL
required	NULL
for	NULL
p12	NULL
``	NULL
binding	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
bottom	NULL
panel	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
.	NULL

The	NULL
BAA	NULL
mutant	NULL
,	NULL
which	NULL
lacks	NULL
amino	NULL
acids	NULL
313	NULL
to	NULL
382	NULL
,	NULL
also	NULL
did	NULL
not	NULL
bind	NULL
p12	NULL
,	NULL
whereas	NULL
the	NULL
BAS	NULL
mutant	NULL
(	NULL
A267-322	NULL
)	NULL
did	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
bottom	NULL
panels	NULL
,	NULL
lanes	NULL
13	NULL
and	NULL
14	NULL
)	NULL
,	NULL
further	NULL
supporting	NULL
this	NULL
idea	NULL
.	NULL

Because	NULL
the	NULL
BAH	NULL
mutant	NULL
coprecipitated	NULL
more	NULL
p12	NULL
!	NULL

when	NULL
increased	NULL
than	NULL
the	NULL
B35	NULL
,	NULL
mutant	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
bottom	NULL
panel	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
the	NULL
binding	NULL
site	NULL
of	NULL
p12	NULL
``	NULL
on	NULL
the	NULL
IL-2R	NULL
B	NULL
chain	NULL
extended	NULL
beyond	NULL
amino	NULL
acid	NULL
350	NULL
,	NULL
which	NULL
is	NULL
present	NULL
in	NULL
the	NULL
BAH	NULL
mutant	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
top	NULL
panel	NULL
)	NULL
.	NULL

To	NULL
do	NULL
this	NULL
,	NULL
3	NULL
additional	NULL
deletion	NULL
mutants	NULL
were	NULL
constructed	NULL
and	NULL
coexpressed	NULL
with	NULL
p12	NULL
``	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
top	NULL
panel	NULL
)	NULL
.	NULL

Coprecipitation	NULL
of	NULL
p12	NULL
``	NULL
was	NULL
observed	NULL
with	NULL
the	NULL
BAST	NULL
1395-350	NULL
mutant	NULL
,	NULL
whereas	NULL
neither	NULL
BAST	NULL
1359433	NULL
nor	NULL
BAST	NULL
;	NULL
399.5325	NULL
coprecipitated	NULL
p12	NULL
``	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
bottom	NULL
panel	NULL
,	NULL
lanes	NULL
18-20	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
primary	NULL
binding	NULL
site	NULL
of	NULL
p12	NULL
!	NULL

to	NULL
the	NULL
IL-2R	NULL
B	NULL
chain	NULL
appears	NULL
to	NULL
be	NULL
proximal	NULL
to	NULL
amino	NULL
acid	NULL
350	NULL
,	NULL
although	NULL
there	NULL
could	NULL
be	NULL
additional	NULL
contacts	NULL
beyond	NULL
this	NULL
region	NULL
.	NULL

Importantly	NULL
,	NULL
this	NULL
region	NULL
was	NULL
previously	NULL
shown	NULL
to	NULL
be	NULL
critical	NULL
for	NULL
the	NULL
recruitment	NULL
of	NULL
Jak1	NULL
and	NULL
Jak3	NULL
after	NULL
IL-2	NULL
signaling	NULL
.	NULL
``	NULL

p12	NULL
!	NULL

increases	NULL
STAT5b	NULL
DNA	NULL
binding	NULL
activity	NULL
Because	NULL
p12	NULL
``	NULL
binds	NULL
the	NULL
IL-2R	NULL
B	NULL
chain	NULL
in	NULL
a	NULL
region	NULL
involved	NULL
in	NULL
transduction	NULL
of	NULL
the	NULL
IL-2	NULL
signal	NULL
,	NULL
we	NULL
hypothesized	NULL
that	NULL
p12	NULL
``	NULL
could	NULL
modulate	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
effector	NULL
of	NULL
IL-2	NULL
signaling	NULL
,	NULL
STATS	NULL
.	NULL

To	NULL
investigate	NULL
this	NULL
hypothesis	NULL
,	NULL
the	NULL
IL-2R	NULL
signaling	NULL
path	NULL
A	NULL
91214111	NULL
l	NULL
:	NULL
Figure	NULL
1	NULL
.	NULL

The	NULL
p12	NULL
'	NULL
protein	NULL
binds	NULL
the	NULL
acidic	NULL
region	NULL
of	NULL
IL-2R	NULL
B	NULL
between	NULL
residues	NULL
330	NULL
and	NULL
350	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
representation	NULL
of	NULL
the	NULL
IL-2R	NULL
B-chain	NULL
truncation	NULL
and	NULL
deletion	NULL
mutants	NULL
.	NULL

Middle	NULL
panels	NULL
show	NULL
controls	NULL
for	NULL
expression	NULL
of	NULL
the	NULL
IL-2R	NULL
$	NULL
truncation	NULL
mutants	NULL
and	NULL
p12	NULL
.	NULL

(	NULL
B	NULL
)	NULL
p12	NULL
}	NULL
,	NULL
,	NULL
,	NULL
[	NULL
Z	NULL
Coprecipitation	NULL
of	NULL
p12	NULL
!	NULL

with	NULL
the	NULL
IL-2R	NULL
B	NULL
mutants	NULL
.	NULL

IP	NULL
indicates	NULL
immunoprecipitation	NULL
;	NULL
WB	NULL
,	NULL
Western	NULL
blot	NULL
.	NULL

HTLV-1	NULL
p12	NULL
!	NULL

ACTIVATES	NULL
STATS	NULL
_	NULL
825	NULL
way	NULL
was	NULL
reconstituted	NULL
in	NULL
a	NULL
transient	NULL
transfection	NULL
system	NULL
``	NULL
``	NULL
in	NULL
which	NULL
IL-2R	NULL
B	NULL
,	NULL
y	NULL
,	NULL
,	NULL
Jak3	NULL
,	NULL
and	NULL
STAT	NULL
5b	NULL
proteins	NULL
were	NULL
coexpressed	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
p12	NULL
'	NULL
.	NULL

In	NULL
this	NULL
experimental	NULL
system	NULL
,	NULL
the	NULL
phosphorylation	NULL
and	NULL
DNA	NULL
binding	NULL
of	NULL
STATS5	NULL
can	NULL
be	NULL
assessed	NULL
before	NULL
and	NULL
after	NULL
IL-2	NULL
triggering	NULL
of	NULL
cells	NULL
.	NULL

COS-7	NULL
cells	NULL
were	NULL
pulsed	NULL
with	NULL
IL-2	NULL
for	NULL
20	NULL
minutes	NULL
,	NULL
and	NULL
nuclear	NULL
lysates	NULL
were	NULL
evaluated	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
activated	NULL
STAT	NULL
5b	NULL
by	NULL
measuring	NULL
STATS5	NULL
binding	NULL
to	NULL
the	NULL
B-casein	NULL
probe	NULL
in	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSAs	NULL
)	NULL
as	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

''	NULL
A	NULL
2-	NULL
to	NULL
4-fold	NULL
increase	NULL
in	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
STATS	NULL
binding	NULL
to	NULL
the	NULL
B-casein	NULL
probe	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
p12	NULL
!	NULL

(	NULL
Figure	NULL
2A	NULL
,	NULL
top	NULL
panel	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Results	NULL
with	NULL
controls	NULL
for	NULL
equivalent	NULL
expression	NULL
of	NULL
IL-2R	NULL
(	NULL
and	NULL
p12	NULL
``	NULL
and	NULL
the	NULL
association	NULL
of	NULL
p12	NULL
``	NULL
with	NULL
the	NULL
IL-2R	NULL
B	NULL
chain	NULL
are	NULL
also	NULL
shown	NULL
in	NULL
Figure	NULL
2A	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
findings	NULL
suggest	NULL
that	NULL
p12	NULL
``	NULL
increases	NULL
STATS	NULL
DNA	NULL
binding	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
and	NULL
that	NULL
less	NULL
IL-2	NULL
is	NULL
required	NULL
to	NULL
promote	NULL
STAT	NULL
5b	NULL
binding	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
p12	NULL
.	NULL

p12	NULL
!	NULL

does	NULL
not	NULL
influence	NULL
degradation	NULL
of	NULL
activated	NULL
STATSb	NULL
IL-2-induced	NULL
STATS	NULL
activation	NULL
is	NULL
tightly	NULL
regulated	NULL
by	NULL
dephosphorylation	NULL
and	NULL
protein	NULL
degradation	NULL
.	NULL
``	NULL

To	NULL
investigate	NULL
whether	NULL
the	NULL
increase	NULL
in	NULL
p12	NULL
-induced	NULL
STATS	NULL
activation	NULL
resulted	NULL
from	NULL
a	NULL
delay	NULL
in	NULL
its	NULL
degradation	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
decay	NULL
of	NULL
STATS	NULL
binding	NULL
activity	NULL
after	NULL
IL-2	NULL
pulsing	NULL
and	NULL
removal	NULL
of	NULL
the	NULL
ligand	NULL
.	NULL

Higher	NULL
levels	NULL
of	NULL
STAT5	NULL
binding	NULL
activity	NULL
were	NULL
detected	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
p12	NULL
``	NULL
at	NULL
all	NULL
time	NULL
points	NULL
after	NULL
the	NULL
IL-2	NULL
washout	NULL
(	NULL
Figure	NULL
2B	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
rate	NULL
of	NULL
decay	NULL
of	NULL
the	NULL
STATS	NULL
binding	NULL
activity	NULL
did	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
affected	NULL
by	NULL
p12	NULL
,	NULL
since	NULL
the	NULL
amount	NULL
of	NULL
STAT	NULL
5b	NULL
binding	NULL
to	NULL
the	NULL
B-casein	NULL
probe	NULL
was	NULL
reduced	NULL
by	NULL
about	NULL
50	NULL
%	NULL
at	NULL
80	NULL
minutes	NULL
(	NULL
Figure	NULL
2C	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
p12	NULL
``	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
increase	NULL
IL-2R	NULL
signaling	NULL
by	NULL
delaying	NULL
STATS	NULL
inactivation	NULL
or	NULL
degradation	NULL
.	NULL

B	NULL
BAST	NULL
Bszo	NULL
Basso	NULL
BAH	NULL
BAA	NULL
BaS	NULL
+P	NULL
12	NULL
hag	NULL
$	NULL
&	NULL
&	NULL
+p12	NULL
)	NULL
+p12\	NULL
?	NULL

I	NULL
4	NULL
P	NULL
s	NULL
Hat	NULL
q-	NULL
HA1	NULL
e	NULL
A455	NULL
?	NULL

?	NULL

?	NULL

¥	NULL
8	NULL
s	NULL
p33	NULL
#	NULL
M	NULL
C	NULL
¥	NULL
_-	NULL
666	NULL
&	NULL
&	NULL
a	NULL
a	NULL
¢	NULL
of	NULL
GJ	NULL
$	NULL
Paa	NULL
dG	NULL
4	NULL
a	NULL
4	NULL
FG	NULL
f	NULL
#	NULL
8	NULL
.	NULL

,	NULL
a	NULL
a	NULL
=s	NULL
i	NULL
in	NULL
e	NULL
__	NULL
@	NULL
#	NULL
iP	NULL
:	NULL
ROB	NULL
»	NULL
a.	NULL
I	NULL
v	NULL
WB	NULL
:	NULL
ErdA	NULL
..	NULL
be	NULL
dbo	NULL
-	NULL
tz	NULL
.	NULL

e—	NULL
IP	NULL
:	NULL
a-HA1	NULL
wus	NULL
--	NULL
wae	NULL
w-	NULL
sme	NULL
crus	NULL
ads	NULL
-	NULL
-	NULL
«	NULL
WB	NULL
:	NULL
a-HA1	NULL
ik	NULL
IP	NULL
:	NULL
RDG	NULL
ae	NULL
wite	NULL
e	NULL
ne	NULL
*e	NULL
WB	NULL
:	NULL
a-HA1	NULL
15	NULL
16	NULL
17	NULL
18	NULL
19	NULL
20	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
Figure	NULL
2	NULL
.	NULL

The	NULL
p12	NULL
!	NULL

protein	NULL
increases	NULL
STATSb	NULL
DNA	NULL
binding	NULL
and	NULL
does	NULL
not	NULL
interfere	NULL
with	NULL
STAT5b	NULL
degradation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EMSA	NULL
of	NULL
lysates	NULL
from	NULL
COS-7	NULL
cells	NULL
.	NULL

Top	NULL
panel	NULL
shows	NULL
control	NULL
for	NULL
the	NULL
amount	NULL
of	NULL
IL-2R	NULL
B	NULL
expression	NULL
on	NULL
Western	NULL
blot	NULL
analysis	NULL
,	NULL
analysis	NULL
of	NULL
p12	NULL
!	NULL

expression	NULL
by	NULL
Western	NULL
blotting	NULL
,	NULL
and	NULL
p12	NULL
!	NULL

and	NULL
IL-2R	NULL
B	NULL
chain	NULL
coprecipita-tion	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Transfected	NULL
cells	NULL
were	NULL
pulsed	NULL
with	NULL
10	NULL
nM	NULL
IL-2	NULL
for	NULL
826	NULL
-	NULL
NICOT	NULL
etal	NULL
JAK3	NULL
+	NULL
+	NULL
1L-287	NULL
,	NULL
+	NULL
+	NULL
IL-2R8	NULL
+	NULL
+	NULL
STATSb	NULL
+	NULL
+	NULL
p12	NULL
)	NULL
-	NULL
+	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
“	NULL
u	NULL
STATSb+	NULL
hab	NULL
i	NULL
tod	NULL
but	NULL
£4	NULL
12-0—	NULL
>	NULL
.	NULL

#	NULL
10.0	NULL
;	NULL
-1	NULL
2	NULL
£	NULL
|-€	NULL
so|	NULL
--	NULL
-	NULL
WB	NULL
:	NULL
ErdA	NULL
[	NULL
s-	NULL
C®®	NULL
®	NULL
E	NULL
sol-1	NULL
2	NULL
a	NULL
3	NULL
10-P12	NULL
will	NULL
as	NULL
WB	NULL
:	NULL
a-AU1	NULL
5	NULL
2-0	NULL
;	NULL
1	NULL
2	NULL
F	NULL
20	NULL
minutes	NULL
,	NULL
washed	NULL
,	NULL
incubated	NULL
in	NULL
medium	NULL
without	NULL
IL-2	NULL
for	NULL
the	NULL
indicated	NULL
times	NULL
,	NULL
lysed	NULL
,	NULL
and	NULL
processed	NULL
for	NULL
EMSA	NULL
as	NULL
in	NULL
Figure	NULL
2A	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Graph	NULL
shows	NULL
quantitation	NULL
of	NULL
the	NULL
data	NULL
in	NULL
Figure	NULL
2B	NULL
,	NULL
obtained	NULL
by	NULL
using	NULL
a	NULL
PhosphorImager	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
,	NULL
Sunnyvale	NULL
,	NULL
CA	NULL
}	NULL
.	NULL

C	NULL
indicates	NULL
con-trol	NULL
;	NULL
IP	NULL
,	NULL
immunoprecipitation	NULL
;	NULL
WB	NULL
,	NULL
Western	NULL
blot	NULL
.	NULL

IP	NULL
:	NULL
a-AU1	NULL
:	NULL
B-	NULL
«	NULL
*	NULL
WB	NULL
:	NULL
ErdA	NULL
1	NULL
2	NULL
balk	NULL
k	NULL
kdbabk	NULL
``	NULL
C	NULL
20	NULL
40	NULL
80	NULL
C	NULL
20	NULL
40	NULL
80	NULL
+p12	NULL
``	NULL
Time	NULL
after	NULL
IL-2	NULL
removal	NULL
{	NULL
minutes	NULL
)	NULL
p12	NULL
!	NULL

binding	NULL
to	NULL
the	NULL
IL-2R	NULL
B	NULL
chain	NULL
is	NULL
necessary	NULL
to	NULL
increase	NULL
STATS5b	NULL
transcriptional	NULL
activity	NULL
To	NULL
assess	NULL
whether	NULL
the	NULL
increased	NULL
STAT	NULL
5b	NULL
DNA	NULL
binding	NULL
induced	NULL
by	NULL
p12	NULL
``	NULL
also	NULL
resulted	NULL
in	NULL
increased	NULL
transcriptional	NULL
activity	NULL
of	NULL
STAT	NULL
5b	NULL
,	NULL
the	NULL
IL-2R	NULL
signaling	NULL
pathway	NULL
was	NULL
reconstituted	NULL
in	NULL
293T	NULL
cells	NULL
and	NULL
a	NULL
B-casein	NULL
promoter	NULL
luciferase	NULL
reporter	NULL
gene	NULL
was	NULL
used	NULL
to	NULL
measure	NULL
STAT5b	NULL
transcriptional	NULL
activation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
p12	NULL
``	NULL
.	NULL

We	NULL
found	NULL
that	NULL
p12	NULL
``	NULL
increased	NULL
STAT5b	NULL
transcriptional	NULL
activity	NULL
by	NULL
approximately	NULL
2-fold	NULL
to	NULL
3-fold	NULL
(	NULL
Figure	NULL
3A	NULL
)	NULL
;	NULL
this	NULL
increase	NULL
was	NULL
also	NULL
evident	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
amounts	NULL
of	NULL
IL-2	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
.	NULL

Approximately	NULL
10-fold	NULL
less	NULL
IL-2	NULL
was	NULL
required	NULL
to	NULL
obtain	NULL
an	NULL
A	NULL
B	NULL
3	NULL
Control	NULL
au	NULL
p12	NULL
CI	NULL
Control	NULL
mi	NULL
p12	NULL
c	NULL
g	NULL
70	NULL
2	NULL
EE	NULL
]	NULL
&	NULL
2	NULL
§	NULL
60	NULL
B	NULL
£	NULL
so	NULL
®	NULL
§	NULL
40	NULL
3	NULL
1	NULL
3	NULL
30	NULL
a	NULL
o	NULL
u	NULL
.	NULL

20	NULL
10	NULL
0	NULL
0	NULL
,	NULL
p12	NULL
:	NULL
=_	NULL
+	NULL
p12	NULL
:	NULL
(	NULL
~	NULL
*	NULL
=	NULL
_+	NULL
-	NULL
_+	NULL
tL-2	NULL
(	NULL
nM	NULL
)	NULL
0	NULL
IL-2	NULL
(	NULL
nM	NULL
)	NULL
_	NULL
0.1	NULL
1.0	NULL
10	NULL
40	NULL
250	NULL
35	NULL
8	NULL
B	NULL
200	NULL
5	NULL
30	NULL
5	NULL
2	NULL
25	NULL
i	NULL
150	NULL
§	NULL
20	NULL
£	NULL
3	NULL
3	NULL
v	NULL
s	NULL
_	NULL
100	NULL
2	NULL
CIMedia	NULL
2	NULL
E	NULL
10	NULL
mmiL-2	NULL
(	NULL
10nM	NULL
)	NULL
E	NULL
2	NULL
&	NULL
so	NULL
5	NULL
0	NULL
s	NULL
PARC	NULL
Can	NULL
ti	NULL
=	NULL
t/	NULL
(	NULL
-	NULL
*	NULL
(	NULL
-	NULL
ti-	NULL
+	NULL
,	NULL
-	NULL
,	NULL
-	NULL
+	NULL
IL-2R	NULL
No	NULL
No	NULL
_	NULL
No	NULL
IL-2R	NULL
:	NULL
;	NULL
-	NULL
WT	NULL
WT	NULL
AA	NULL
-	NULL
AA	NULL
beta	NULL
gamma	NULL
Jak3	NULL
p12	NULL
:	NULL
-	NULL
4	NULL
-	NULL
+	NULL
Figure	NULL
3	NULL
.	NULL

STATS	NULL
transcriptional	NULL
activation	NULL
induced	NULL
by	NULL
p12	NULL
!	NULL

depends	NULL
on	NULL
binding	NULL
to	NULL
the	NULL
IL-2R	NULL
B	NULL
chain	NULL
.	NULL

In	NULL
this	NULL
experiment	NULL
,	NULL
2931	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
plasmids	NULL
expressing	NULL
IL-2	NULL
B	NULL
,	NULL
IL-2R	NULL
y	NULL
,	NULL
,	NULL
Jak3	NULL
,	NULL
and	NULL
STATSb	NULL
with	NULL
or	NULL
without	NULL
p12	NULL
'	NULL
.	NULL

IL-2	NULL
was	NULL
added	NULL
20	NULL
hours	NULL
later	NULL
;	NULL
after	NULL
24	NULL
hours	NULL
,	NULL
activation	NULL
of	NULL
the	NULL
B-casein	NULL
luciferase	NULL
reporter	NULL
was	NULL
determined	NULL
by	NULL
using	NULL
a	NULL
luminometer	NULL
.	NULL

A	NULL
Renilla	NULL
luciferase	NULL
reporter	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
was	NULL
used	NULL
to	NULL
control	NULL
transfection	NULL
efficiency	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Basal	NULL
transcriptional	NULL
activation	NULL
of	NULL
STATSb	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
.	NULL

(	NULL
B	NULL
)	NULL
STATSb	NULL
activation	NULL
with	NULL
increasing	NULL
amounts	NULL
of	NULL
IL-2	NULL
(	NULL
nM	NULL
)	NULL
.	NULL

The	NULL
error	NULL
bars	NULL
in	NULL
panels	NULL
A	NULL
,	NULL
B	NULL
,	NULL
and	NULL
D	NULL
indicate	NULL
the	NULL
SE	NULL
from	NULL
3	NULL
independent	NULL
experiments	NULL
.	NULL

Panel	NULL
C	NULL
shows	NULL
a	NULL
representative	NULL
experiment	NULL
.	NULL

At	NULL
least	NULL
3	NULL
independent	NULL
experiments	NULL
were	NULL
done	NULL
to	NULL
obtain	NULL
the	NULL
results	NULL
shown	NULL
in	NULL
each	NULL
panel	NULL
.	NULL

WT	NULL
indicates	NULL
wild-type	NULL
IL-2R	NULL
B	NULL
,	NULL
and	NULL
A	NULL
indicates	NULL
the	NULL
BAA	NULL
mutant	NULL
.	NULL

C	NULL
204080	NULL
c	NULL
204080	NULL
Time	NULL
after	NULL
IL-2	NULL
removal	NULL
{	NULL
minutes	NULL
}	NULL
equivalent	NULL
level	NULL
of	NULL
STAT	NULL
5b	NULL
transcriptional	NULL
activity	NULL
,	NULL
as	NULL
indicated	NULL
,	NULL
for	NULL
example	NULL
,	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
luciferase	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
p12	NULL
``	NULL
with	NULL
1	NULL
nM	NULL
IL-2	NULL
was	NULL
equivalent	NULL
to	NULL
that	NULL
obtained	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
p12	NULL
``	NULL
with	NULL
10	NULL
nM	NULL
IL-2	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
.	NULL

The	NULL
increase	NULL
in	NULL
STAT	NULL
5b	NULL
transcriptional	NULL
activity	NULL
induced	NULL
by	NULL
p12	NULL
``	NULL
required	NULL
the	NULL
presence	NULL
of	NULL
all	NULL
components	NULL
of	NULL
the	NULL
IL-2R	NULL
pathway	NULL
,	NULL
since	NULL
the	NULL
absence	NULL
of	NULL
B	NULL
,	NULL
y	NULL
,	NULL
,	NULL
or	NULL
Jak3	NULL
resulted	NULL
in	NULL
loss	NULL
of	NULL
STATS	NULL
activation	NULL
despite	NULL
the	NULL
presence	NULL
of	NULL
p12	NULL
``	NULL
(	NULL
Figure	NULL
3C	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
p12	NULL
``	NULL
binding	NULL
to	NULL
the	NULL
B	NULL
chain	NULL
at	NULL
amino	NULL
acids	NULL
330	NULL
to	NULL
350	NULL
was	NULL
also	NULL
essential	NULL
for	NULL
p12	NULL
``	NULL
induction	NULL
of	NULL
STAT5b	NULL
activity	NULL
because	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
BAA	NULL
mutant	NULL
,	NULL
which	NULL
maintains	NULL
its	NULL
ability	NULL
to	NULL
transduce	NULL
the	NULL
IL-2	NULL
signal	NULL
``	NULL
(	NULL
although	NULL
at	NULL
a	NULL
lower	NULL
level	NULL
)	NULL
but	NULL
lacks	NULL
the	NULL
330-	NULL
to	NULL
350-amino	NULL
acid	NULL
stretch	NULL
that	NULL
binds	NULL
p12	NULL
'	NULL
,	NULL
no	NULL
increase	NULL
in	NULL
STAT5b	NULL
activity	NULL
was	NULL
observed	NULL
(	NULL
Figure	NULL
3D	NULL
)	NULL
.	NULL

Increased	NULL
transcriptional	NULL
activation	NULL
was	NULL
also	NULL
observed	NULL
when	NULL
STAT	NULL
5a	NULL
was	NULL
used	NULL
instead	NULL
of	NULL
STAT	NULL
5b	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
results	NULL
show	NULL
that	NULL
p12	NULL
!	NULL

decreases	NULL
the	NULL
threshold	NULL
of	NULL
IL-2	NULL
signaling	NULL
and	NULL
that	NULL
this	NULL
effect	NULL
depends	NULL
on	NULL
binding	NULL
to	NULL
the	NULL
IL-2R	NULL
B	NULL
chain	NULL
.	NULL

Because	NULL
the	NULL
B	NULL
and	NULL
y	NULL
,	NULL
chains	NULL
are	NULL
also	NULL
part	NULL
of	NULL
the	NULL
IL-15R	NULL
,	NULL
it	NULL
would	NULL
be	NULL
interesting	NULL
to	NULL
determine	NULL
whether	NULL
p12	NULL
!	NULL

could	NULL
also	NULL
affect	NULL
IL-1	NULL
5R	NULL
signaling	NULL
.	NULL
``	NULL

p12	NULL
!	NULL

increases	NULL
STATS	NULL
phosphorylation	NULL
and	NULL
DNA	NULL
binding	NULL
in	NULL
primary	NULL
human	NULL
PBMCs	NULL
HTLV-1	NULL
infects	NULL
and	NULL
transforms	NULL
human	NULL
primary	NULL
PBMCs	NULL
both	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
p12	NULL
``	NULL
would	NULL
increase	NULL
STATS	NULL
activation	NULL
in	NULL
its	NULL
natural	NULL
target-cell	NULL
population	NULL
.	NULL

An	NULL
HIV-1-based	NULL
retroviral	NULL
vector	NULL
expressing	NULL
p12	NULL
``	NULL
was	NULL
constructed	NULL
(	NULL
HR'CMV	NULL
p12	NULL
``	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
-tagged	NULL
p12	NULL
``	NULL
was	NULL
assessed	NULL
first	NULL
in	NULL
transfected	NULL
293T	NULL
cells	NULL
by	NULL
Western	NULL
blotting	NULL
,	NULL
and	NULL
the	NULL
characteristic	NULL
doublet	NULL
of	NULL
p12	NULL
!	NULL

was	NULL
readily	NULL
detected	NULL
(	NULL
Figure	NULL
4A	NULL
)	NULL
.	NULL

Transduction	NULL
of	NULL
HR'CMV	NULL
p12	NULL
!	NULL

in	NULL
primary	NULL
human	NULL
PBMCs	NULL
was	NULL
properly	NULL
localized	NULL
in	NULL
the	NULL
ER-Golgi	NULL
compartment	NULL
,	NULL
as	NULL
demonstrated	NULL
by	NULL
confocal	NULL
immunofluorescence	NULL
(	NULL
Figure	NULL
4B	NULL
)	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
effect	NULL
of	NULL
p12	NULL
!	NULL

on	NULL
PBMCs	NULL
,	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
from	NULL
healthy	NULL
volunteers	NULL
were	NULL
infected	NULL
with	NULL
pseudotype	NULL
viruses	NULL
carrying	NULL
p12	NULL
``	NULL
or	NULL
the	NULL
luciferase	NULL
genes	NULL
.	NULL

After	NULL
18	NULL
hours	NULL
,	NULL
PBMCs	NULL
were	NULL
deprived	NULL
of	NULL
serum	NULL
and	NULL
IL-2	NULL
to	NULL
lower	NULL
the	NULL
STATS	NULL
basal	NULL
level	NULL
of	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
pulsed	NULL
for	NULL
10	NULL
minutes	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
IL-2	NULL
,	NULL
and	NULL
STATS	NULL
phosphorylation	NULL
and	NULL
activation	NULL
was	NULL
assessed	NULL
by	NULL
either	NULL
gel-shift	NULL
assay	NULL
or	NULL
Western	NULL
blot	NULL
using	NULL
Ab	NULL
to	NULL
phosphorylated	NULL
STAT5	NULL
.	NULL

The	NULL
expected	NULL
DNA-protein	NULL
complex	NULL
in	NULL
nuclear	NULL
extracts	NULL
of	NULL
cells	NULL
pulsed	NULL
with	NULL
IL-2	NULL
was	NULL
readily	NULL
observed	NULL
by	NULL
using	NULL
the	NULL
B-casein	NULL
probe	NULL
(	NULL
Figure	NULL
4C	NULL
)	NULL
,	NULL
and	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
A	NULL
B	NULL
e	NULL
HR'CMV-pl	NULL
R	NULL
«	NULL
Lue	NULL
$	NULL
35	NULL
``	NULL
C	NULL
p12	NULL
``	NULL
HR'CMV-L	NULL
v	NULL
@	NULL
I	NULL
-	NULL
>	NULL
>	NULL
p12	NULL
-p	NULL
1	NULL
C	NULL
PBL	NULL
HR'CMV-p12	NULL
``	NULL
I	NULL
1000	NULL
I	NULL
I	NULL
#	NULL
8	NULL
-	NULL
op	NULL
ya	NULL
,	NULL
``	NULL
,	NULL
®	NULL
amrs	NULL
..	NULL
..	NULL
tl	NULL
=	NULL
Whit	NULL
!	NULL

PBL	NULL
&	NULL
°	NULL
L	NULL
p	NULL
s	NULL
¢	NULL
ntti	NULL
Acts	NULL
do	NULL
HR'CMV-	NULL
Lue	NULL
4-SS	NULL
.	NULL

ﬂ	NULL
’	NULL
N-STATS	NULL
«	NULL
--	NULL
4-STATL	NULL
p12	NULL
``	NULL
STATS-P	NULL
Figure	NULL
4	NULL
.	NULL

HR'CMV	NULL
p12	NULL
'	NULL
transduction	NULL
in	NULL
primary	NULL
PBMCs	NULL
increases	NULL
STATS	NULL
activation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
HR'CMV	NULL
p12	NULL
!	NULL

and	NULL
HR'CMV-Luc	NULL
constructs	NULL
were	NULL
transfected	NULL
in	NULL
2931	NULL
cells	NULL
and	NULL
protein	NULL
extracts	NULL
subjected	NULL
to	NULL
immunoprecipitation	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
using	NULL
«	NULL
HA1	NULL
Ab	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Confocal	NULL
immunofluorescence	NULL
of	NULL
PBMCs	NULL
after	NULL
infection	NULL
with	NULL
pseudotype	NULL
viruses	NULL
expressing	NULL
either	NULL
Luc	NULL
or	NULL
p12	NULL
!	NULL

.	NULL

(	NULL
C	NULL
)	NULL
Increased	NULL
STATS	NULL
DNA	NULL
binding	NULL
was	NULL
indicated	NULL
by	NULL
EMSA	NULL
.	NULL

STATS	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
measured	NULL
by	NULL
using	NULL
a	NULL
P-labeled	NULL
B-casein	NULL
GAS	NULL
element	NULL
.	NULL

B	NULL
indicates	NULL
basal	NULL
STATS	NULL
activity	NULL
;	NULL
S	NULL
,	NULL
starved	NULL
for	NULL
serum	NULL
and	NULL
IL-2	NULL
overnight	NULL
;	NULL
minus	NULL
sign	NULL
,	NULL
no	NULL
Ab	NULL
to	NULL
STATS	NULL
after	NULL
pulse	NULL
with	NULL
1000	NULL
U	NULL
IL-2	NULL
;	NULL
plus	NULL
sign	NULL
,	NULL
Ab	NULL
to	NULL
STATS	NULL
was	NULL
added	NULL
;	NULL
and	NULL
1000	NULL
,	NULL
pulse	NULL
with	NULL
1000	NULL
IU	NULL
IL-2	NULL
.	NULL

Cells	NULL
were	NULL
pulsed	NULL
with	NULL
various	NULL
amounts	NULL
of	NULL
IL-2	NULL
(	NULL
0	NULL
,	NULL
0.1	NULL
,	NULL
1	NULL
,	NULL
10	NULL
,	NULL
and	NULL
100	NULL
IU/mL	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
using	NULL
a	NULL
phospho-STATS-specific	NULL
Ab	NULL
was	NULL
done	NULL
on	NULL
the	NULL
same	NULL
cellular	NULL
extracts	NULL
used	NULL
in	NULL
the	NULL
gel-shift	NULL
assay	NULL
.	NULL

the	NULL
identity	NULL
of	NULL
STATS	NULL
in	NULL
the	NULL
DNA	NULL
complex	NULL
was	NULL
demonstrated	NULL
by	NULL
using	NULL
a	NULL
specific	NULL
STATS	NULL
Ab	NULL
to	NULL
supershift	NULL
the	NULL
complex	NULL
(	NULL
Figure	NULL
4C	NULL
)	NULL
.	NULL

At	NULL
10	NULL
U	NULL
and	NULL
100	NULL
U	NULL
IL-2	NULL
,	NULL
the	NULL
level	NULL
of	NULL
STAT5-DNA	NULL
complex	NULL
was	NULL
a	NULL
few-fold	NULL
higher	NULL
in	NULL
cells	NULL
infected	NULL
with	NULL
HR'CMV	NULL
p12	NULL
``	NULL
than	NULL
in	NULL
cells	NULL
infected	NULL
with	NULL
the	NULL
control	NULL
HR'CMV-Luc	NULL
virus	NULL
,	NULL
suggesting	NULL
that	NULL
p12	NULL
``	NULL
may	NULL
enhance	NULL
STAT5	NULL
phosphorylation	NULL
and	NULL
DNA	NULL
binding	NULL
.	NULL

To	NULL
confirm	NULL
this	NULL
finding	NULL
,	NULL
the	NULL
same	NULL
nuclear	NULL
lysates	NULL
were	NULL
used	NULL
in	NULL
Western	NULL
blot	NULL
analysis	NULL
using	NULL
a	NULL
mouse	NULL
monoclonal	NULL
Ab	NULL
to	NULL
the	NULL
phosphorylated	NULL
STATS	NULL
.	NULL

This	NULL
experiment	NULL
confirmed	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
higher	NULL
level	NULL
of	NULL
phosphorylated	NULL
STAT	NULL
5	NULL
in	NULL
cells	NULL
infected	NULL
with	NULL
HR'CMV	NULL
p12	NULL
``	NULL
than	NULL
in	NULL
those	NULL
infected	NULL
with	NULL
HR'CMV-Luc	NULL
after	NULL
pulsing	NULL
with	NULL
IL-2	NULL
(	NULL
Figure	NULL
4D	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
as	NULL
observed	NULL
in	NULL
COS-7	NULL
cells	NULL
,	NULL
p12	NULL
!	NULL

increased	NULL
STATS	NULL
activation	NULL
in	NULL
primary	NULL
human	NULL
PBMCs	NULL
.	NULL

HTLV-1	NULL
p12	NULL
!	NULL

ACTIVATES	NULL
STATS	NULL
-	NULL
827	NULL
p12	NULL
!	NULL

decreases	NULL
the	NULL
IL-2	NULL
requirement	NULL
for	NULL
T-cell	NULL
proliferation	NULL
An	NULL
expected	NULL
consequence	NULL
of	NULL
an	NULL
increased	NULL
basal	NULL
level	NULL
of	NULL
STAT5	NULL
activation	NULL
is	NULL
that	NULL
cell	NULL
proliferation	NULL
may	NULL
occur	NULL
with	NULL
a	NULL
lower	NULL
concentration	NULL
of	NULL
exogenous	NULL
IL-2	NULL
.	NULL

To	NULL
investigate	NULL
this	NULL
hypothesis	NULL
,	NULL
PBMCs	NULL
from	NULL
healthy	NULL
volunteers	NULL
were	NULL
isolated	NULL
,	NULL
washed	NULL
in	NULL
PBS	NULL
,	NULL
and	NULL
either	NULL
used	NULL
as	NULL
such	NULL
or	NULL
after	NULL
suboptimal	NULL
stimulation	NULL
with	NULL
either	NULL
PHA	NULL
(	NULL
1	NULL
ng/mL	NULL
)	NULL
or	NULL
CD3/CD28	NULL
(	NULL
0.5	NULL
ng/mL	NULL
)	NULL
for	NULL
24	NULL
hours	NULL
before	NULL
infection	NULL
with	NULL
HR'CMV	NULL
p12	NULL
``	NULL
or	NULL
HR'CMV-Luc	NULL
pseudotype	NULL
viruses	NULL
.	NULL

Infected	NULL
cells	NULL
were	NULL
then	NULL
divided	NULL
into	NULL
4	NULL
aliquots	NULL
and	NULL
plated	NULL
in	NULL
duplicate	NULL
in	NULL
96-well	NULL
plates	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
2.5	NULL
,	NULL
5	NULL
,	NULL
and	NULL
10	NULL
or	NULL
100	NULL
U	NULL
IL-2	NULL
.	NULL

Cellular	NULL
proliferation	NULL
was	NULL
monitored	NULL
as	NULL
described	NULL
.	NULL
``	NULL

''	NULL
The	NULL
p12	NULL
``	NULL
-transduced	NULL
PBMCs	NULL
stimulated	NULL
in	NULL
suboptimal	NULL
conditions	NULL
proliferated	NULL
faster	NULL
than	NULL
the	NULL
Luc-transduced	NULL
PBMC	NULL
control	NULL
(	NULL
Figure	NULL
5	NULL
)	NULL
and	NULL
,	NULL
although	NULL
this	NULL
effect	NULL
was	NULL
evident	NULL
with	NULL
2.5	NULL
U	NULL
and	NULL
5	NULL
U	NULL
IL-2	NULL
(	NULL
Figure	NULL
5D-E	NULL
)	NULL
,	NULL
it	NULL
was	NULL
lost	NULL
at	NULL
higher	NULL
concentrations	NULL
'	NULL
``	NULL
of	NULL
the	NULL
ligand	NULL
(	NULL
Figure	NULL
5E	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
this	NULL
effect	NULL
was	NULL
evident	NULL
only	NULL
within	NULL
the	NULL
first	NULL
few	NULL
days	NULL
after	NULL
infection	NULL
,	NULL
it	NULL
became	NULL
undetectable	NULL
4	NULL
days	NULL
after	NULL
infection	NULL
(	NULL
Figure	NULL
5F	NULL
)	NULL
,	NULL
and	NULL
it	NULL
was	NULL
not	NULL
observed	NULL
at	NULL
all	NULL
in	NULL
unstimulated	NULL
resting	NULL
PBMCs	NULL
(	NULL
Figure	NULL
5A-C	NULL
)	NULL
.	NULL

Other	NULL
studies	NULL
suggested	NULL
that	NULL
p12	NULL
``	NULL
may	NULL
affect	NULL
HTLV-1	NULL
infectivity	NULL
by	NULL
promoting	NULL
activation	NULL
of	NULL
quiescent	NULL
primary	NULL
T	NULL
lymphocytes	NULL
.	NULL

``	NULL
!	NULL

Our	NULL
results	NULL
,	NULL
obtained	NULL
from	NULL
experiments	NULL
with	NULL
samples	NULL
from	NULL
3	NULL
different	NULL
donors	NULL
,	NULL
do	NULL
not	NULL
seem	NULL
to	NULL
support	NULL
this	NULL
conclusion	NULL
,	NULL
since	NULL
p12	NULL
!	NULL

did	NULL
not	NULL
stimulate	NULL
T	NULL
cells	NULL
to	NULL
proliferate	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
an	NULL
exogenous	NULL
activating	NULL
signal	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
data	NULL
suggest	NULL
that	NULL
p12	NULL
!	NULL

expression	NULL
alone	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
activate	NULL
T	NULL
cells	NULL
but	NULL
that	NULL
it	NULL
enables	NULL
T	NULL
cells	NULL
,	NULL
activated	NULL
in	NULL
suboptimal	NULL
conditions	NULL
,	NULL
to	NULL
proliferate	NULL
even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
low	NULL
level	NULL
of	NULL
IL-2	NULL
.	NULL

Discussion	NULL
HTLV-1	NULL
has	NULL
persisted	NULL
in	NULL
nonhuman	NULL
and	NULL
human	NULL
primates	NULL
for	NULL
thousands	NULL
of	NULL
years	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
the	NULL
finding	NULL
of	NULL
proviral	NULL
DNA	NULL
in	NULL
Andean	NULL
mummies	NULL
.	NULL
``	NULL

HTLV-1	NULL
virions	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
HIV-1	NULL
virions	NULL
,	NULL
are	NULL
poorly	NULL
infectious	NULL
in	NULL
vitro	NULL
,	NULL
and	NULL
HTLV-1	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
transmitted	NULL
efficiently	NULL
mainly	NULL
through	NULL
cell-to-cell	NULL
contact	NULL
.	NULL

!	NULL

Therefore	NULL
,	NULL
maintenance	NULL
of	NULL
a	NULL
large	NULL
pool	NULL
of	NULL
long-lasting	NULL
infected	NULL
T	NULL
cells	NULL
carrying	NULL
the	NULL
provirus	NULL
in	NULL
infected	NULL
individuals	NULL
``	NULL
has	NULL
likely	NULL
been	NULL
instrumental	NULL
in	NULL
preventing	NULL
extinction	NULL
of	NULL
HTLV-1	NULL
.	NULL

However	NULL
,	NULL
the	NULL
expansion	NULL
of	NULL
infected	NULL
T	NULL
cells	NULL
does	NULL
not	NULL
occur	NULL
without	NULL
risk	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
in	NULL
1	NULL
%	NULL
to	NULL
2	NULL
%	NULL
of	NULL
individuals	NULL
infected	NULL
with	NULL
HTLV-1	NULL
,	NULL
ATLL	NULL
,	NULL
a	NULL
fatal	NULL
clonal	NULL
disease	NULL
,	NULL
develops	NULL
,	NULL
presumably	NULL
by	NULL
means	NULL
of	NULL
accidental	NULL
accumulation	NULL
of	NULL
somatic	NULL
mutations	NULL
of	NULL
genes	NULL
that	NULL
regulate	NULL
T-cell	NULL
growth	NULL
.	NULL

The	NULL
ways	NULL
in	NULL
which	NULL
HTLV-1	NULL
immortalizes	NULL
T	NULL
cells	NULL
in	NULL
vitro	NULL
likely	NULL
mirror	NULL
the	NULL
mechanisms	NULL
used	NULL
by	NULL
the	NULL
virus	NULL
in	NULL
vivo	NULL
.	NULL

In	NULL
vitro	NULL
,	NULL
the	NULL
viral	NULL
transactivator	NULL
Tax	NULL
overrides	NULL
normal	NULL
mechanisms	NULL
for	NULL
controlling	NULL
cell	NULL
growth	NULL
by	NULL
affecting	NULL
the	NULL
activity	NULL
of	NULL
regulators	NULL
of	NULL
cell-cycle	NULL
progression	NULL
,	NULL
such	NULL
as	NULL
p53	NULL
,	NULL
``	NULL
``	NULL
3°	NULL
the	NULL
Rb	NULL
protein	NULL
,	NULL
``	NULL
and	NULL
MAD1	NULL
,	NULL
*°	NULL
and	NULL
by	NULL
either	NULL
suppressing	NULL
expression	NULL
of	NULL
the	NULL
cell-cycle	NULL
regulators	NULL
c-Myb	NULL
``	NULL
and	NULL
B-Myb	NULL
``	NULL
or	NULL
increasing	NULL
expression	NULL
of	NULL
antiapoptotic	NULL
proteins	NULL
,	NULL
including	NULL
Bcel-X	NULL
#	NULL
>	NULL
and	NULL
Bel-2	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
Tax	NULL
appears	NULL
to	NULL
have	NULL
a	NULL
costimulatory	NULL
effect	NULL
on	NULL
T	NULL
cells	NULL
by	NULL
inducing	NULL
dephosphorylation	NULL
of	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
1	NULL
,	NULL
``	NULL
resulting	NULL
in	NULL
activation	NULL
of	NULL
CD28-responsive	NULL
elements	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
``	NULL
and	NULL
the	NULL
IL-2R	NULL
a	NULL
chain	NULL
,	NULL
``	NULL
which	NULL
together	NULL
with	NULL
the	NULL
B	NULL
and	NULL
y.	NULL
chains	NULL
,	NULL
forms	NULL
the	NULL
high-affinity	NULL
receptor	NULL
for	NULL
IL-2	NULL
.	NULL

However	NULL
,	NULL
although	NULL
Tax	NULL
is	NULL
important	NULL
in	NULL
preventing	NULL
T-cell	NULL
apoptosis	NULL
and	NULL
cell-cycle	NULL
arrest	NULL
,	NULL
its	NULL
immunogenicity	NULL
in	NULL
vivo	NULL
``	NULL
``	NULL
may	NULL
interfere	NULL
with	NULL
the	NULL
ability	NULL
of	NULL
infected	NULL
cells	NULL
to	NULL
survive	NULL
immune	NULL
recognition	NULL
.	NULL

The	NULL
HTLV-1	NULL
p12	NULL
``	NULL
protein	NULL
may	NULL
play	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
this	NULL
regard	NULL
.	NULL

First	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
p12	NULL
``	NULL
to	NULL
target	NULL
the	NULL
MHC	NULL
I	NULL
for	NULL
From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

828	NULL
-	NULL
NICOT	NULL
etal	NULL
BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
-4-Lue	NULL
|	NULL
Figure	NULL
5	NULL
.	NULL

The	NULL
p12	NULL
!	NULL

protein	NULL
increased	NULL
T-cell	NULL
prolifera-	NULL
#	NULL
-p12	NULL
tion	NULL
after	NULL
suboptimal	NULL
antigen	NULL
stimulation	NULL
.	NULL

PBMCs	NULL
from	NULL
healthy	NULL
volunteers	NULL
were	NULL
purified	NULL
by	NULL
the	NULL
Ficoll	NULL
method	NULL
,	NULL
.	NULL

e	NULL
washed	NULL
in	NULL
PBS	NULL
,	NULL
and	NULL
either	NULL
used	NULL
as	NULL
such	NULL
or	NULL
after	NULL
subopti-A	NULL
Unstimulated	NULL
day	NULL
2	NULL
B	NULL
Unstimulated	NULL
day	NULL
3	NULL
C	NULL
Unstimulated	NULL
day	NULL
4	NULL
mal	NULL
stimulation	NULL
with	NULL
0.5	NULL
ng/mL	NULL
CD3/CD28	NULL
Ab	NULL
for	NULL
24	NULL
hours	NULL
$	NULL
s	NULL
before	NULL
infection	NULL
with	NULL
HR'CMV	NULL
p12	NULL
``	NULL
or	NULL
HR'CMV-Luc	NULL
-	NULL
,	NULL
95	NULL
06	NULL
'	NULL
pseudotype	NULL
viruses	NULL
.	NULL

Cellular	NULL
proliferation	NULL
was	NULL
measured	NULL
g	NULL
:	NULL
|	NULL
ssl	NULL
0.7	NULL
}	NULL
by	NULL
using	NULL
a	NULL
Colorimetric	NULL
Cell	NULL
Proliferation	NULL
Kit	NULL
II	NULL
.	NULL

SDs	NULL
were	NULL
%	NULL
``	NULL
4	NULL
8s	NULL
.	NULL

calculated	NULL
from	NULL
2	NULL
independent	NULL
infections	NULL
of	NULL
each	NULL
donor	NULL
3	NULL
``	NULL
04	NULL
]	NULL
sample	NULL
,	NULL
and	NULL
values	NULL
are	NULL
representative	NULL
of	NULL
results	NULL
from	NULL
3	NULL
E	NULL
08	NULL
%	NULL
]	NULL
0.5	NULL
:	NULL
separate	NULL
donors	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
after	NULL
€	NULL
©	NULL
#	NULL
4	NULL
os	NULL
!	NULL

stimulation	NULL
with	NULL
1	NULL
ng/mL	NULL
PHA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

E	NULL
8+	NULL
--	NULL
02	NULL
)	NULL
_-	NULL
034	NULL
A	NULL
uses	NULL
-a	NULL
*s	NULL
af	NULL
_-	NULL
|_	NULL
p-f-f-1	NULL
D	NULL
CD3/CD28	NULL
day	NULL
2	NULL
E	NULL
F	NULL
CD3/CD28	NULL
day	NULL
4	NULL
u.5|	NULL
0.6	NULL
,	NULL
08	NULL
&	NULL
o7|	NULL
--	NULL
§	NULL
``	NULL
5|	NULL
051	NULL
“	NULL
FE	NULL
os	NULL
!	NULL

06	NULL
5035	NULL
,	NULL
04	NULL
i	NULL
05	NULL
3	NULL
04	NULL
|	NULL
E	NULL
0.3	NULL
#	NULL
8	NULL
5	NULL
o25	NULL
0.3	NULL
|	NULL
E	NULL
]	NULL
*	NULL
os	NULL
o2	NULL
-	NULL
:	NULL
02	NULL
0	NULL
25	NULL
5	NULL
10	NULL
J	NULL
25	NULL
5	NULL
10	NULL
0	NULL
25	NULL
05	NULL
19	NULL
M-2units/	NULL
ml	NULL
.	NULL

degradation	NULL
``	NULL
*	NULL
may	NULL
markedly	NULL
decrease	NULL
the	NULL
density	NULL
of	NULL
the	NULL
MHC	NULL
I/viral-peptide	NULL
complexes	NULL
(	NULL
including	NULL
Tax	NULL
peptides	NULL
)	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
and	NULL
render	NULL
the	NULL
infected	NULL
cells	NULL
invisible	NULL
to	NULL
recognition	NULL
by	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

Second	NULL
,	NULL
as	NULL
demonstrated	NULL
in	NULL
this	NULL
study	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
p12	NULL
``	NULL
to	NULL
increase	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
STATS	NULL
activation	NULL
and	NULL
T-cell	NULL
responsiveness	NULL
to	NULL
IL-2	NULL
,	NULL
coupled	NULL
with	NULL
the	NULL
costimulatory	NULL
effect	NULL
of	NULL
Tax	NULL
,	NULL
may	NULL
ultimately	NULL
result	NULL
in	NULL
a	NULL
limited	NULL
burst	NULL
of	NULL
virus	NULL
as	NULL
well	NULL
as	NULL
limited	NULL
replication	NULL
of	NULL
HTLV-l-infected	NULL
T	NULL
cells	NULL
.	NULL

Both	NULL
the	NULL
Tax	NULL
costimulatory	NULL
effect	NULL
and	NULL
the	NULL
increased	NULL
STATS	NULL
activation	NULL
induced	NULL
by	NULL
p12	NULL
!	NULL

appear	NULL
to	NULL
depend	NULL
on	NULL
antigen	NULL
or	NULL
mitogen	NULL
stimulation	NULL
,	NULL
suggesting	NULL
that	NULL
cell-cycle	NULL
entry	NULL
of	NULL
HTLV-1-infected	NULL
T	NULL
cells	NULL
may	NULL
be	NULL
promoted	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
antigen	NULL
stimulation	NULL
in	NULL
the	NULL
microenvi-ronment	NULL
.	NULL

In	NULL
support	NULL
of	NULL
this	NULL
hypothesis	NULL
,	NULL
epidemiologic	NULL
studies	NULL
have	NULL
indicated	NULL
that	NULL
patients	NULL
with	NULL
concomitant	NULL
Strongyloides	NULL
stercoralis	NULL
infection	NULL
have	NULL
a	NULL
higher	NULL
frequency	NULL
of	NULL
ATLL.4**	NULL
'	NULL
Interestingly	NULL
,	NULL
HTLV-1	NULL
and	NULL
HIV-1	NULL
have	NULL
independently	NULL
evolved	NULL
2	NULL
proteins	NULL
(	NULL
p12	NULL
'	NULL
and	NULL
Nef	NULL
)	NULL
with	NULL
similar	NULL
cellular	NULL
targets	NULL
.	NULL

Both	NULL
p12	NULL
``	NULL
and	NULL
Nef	NULL
target	NULL
subunits	NULL
(	NULL
although	NULL
different	NULL
)	NULL
of	NULL
the	NULL
vacuolar	NULL
H+ATPase'*	NULL
``	NULL
``	NULL
;	NULL
p12	NULL
!	NULL

interferes	NULL
with	NULL
trafficking	NULL
of	NULL
MHC	NULL
I	NULL
heavy	NULL
chain	NULL
to	NULL
the	NULL
cell	NULL
surface	NULL
,	NULL
``	NULL
``	NULL
whereas	NULL
Nef	NULL
down-regulates	NULL
the	NULL
MHC	NULL
I	NULL
that	NULL
has	NULL
already	NULL
reached	NULL
the	NULL
cell	NULL
surface	NULL
,	NULL
and	NULL
both	NULL
proteins	NULL
increase	NULL
IL-2	NULL
responsiveness	NULL
(	NULL
though	NULL
by	NULL
different	NULL
mechanisms	NULL
)	NULL
.	NULL

``	NULL
``	NULL
>	NULL
``	NULL
``	NULL
In	NULL
addition	NULL
,	NULL
ablation	NULL
of	NULL
Nef	NULL
and	NULL
p12	NULL
``	NULL
from	NULL
molecular	NULL
clones	NULL
of	NULL
simian	NULL
immunodeficiency	NULL
virus	NULL
and	NULL
HTLV-1	NULL
,	NULL
respectively	NULL
,	NULL
results	NULL
in	NULL
a	NULL
similar	NULL
phenotype	NULL
,	NULL
ie	NULL
,	NULL
their	NULL
absence	NULL
impairs	NULL
viral	NULL
infectivity	NULL
in	NULL
vivo	NULL
,	NULL
but	NULL
their	NULL
presence	NULL
is	NULL
not	NULL
essential	NULL
for	NULL
viral	NULL
infectivity	NULL
or	NULL
replication	NULL
in	NULL
tissue	NULL
culture	NULL
.	NULL
``	NULL

''	NULL
``	NULL
``	NULL
Thus	NULL
,	NULL
the	NULL
3	NULL
'	NULL
region	NULL
of	NULL
both	NULL
human	NULL
retroviruses	NULL
encodes	NULL
proteins	NULL
(	NULL
p12	NULL
!	NULL

and	NULL
Nef	NULL
)	NULL
that	NULL
help	NULL
to	NULL
preserve	NULL
life-long	NULL
infection	NULL
of	NULL
humans	NULL
while	NULL
increasing	NULL
the	NULL
likelihood	NULL
of	NULL
viral	NULL
transmission	NULL
.	NULL

Acknowledgment	NULL
We	NULL
thank	NULL
Steven	NULL
Snodgrass	NULL
for	NULL
editorial	NULL
assistance	NULL
.	NULL

References	NULL
Gallo	NULL
RC	NULL
.	NULL

The	NULL
first	NULL
human	NULL
retrovirus	NULL
.	NULL

Sci	NULL
Am	NULL
.	NULL

1986	NULL
;	NULL
255:88-98	NULL
.	NULL

Berneman	NULL
ZN	NULL
,	NULL
Gartenhaus	NULL
RB	NULL
,	NULL
Reitz	NULL
MS	NULL
Jr	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Expression	NULL
of	NULL
alternatively	NULL
spliced	NULL
human	NULL
T-lymphotropic	NULL
virus	NULL
type	NULL
|	NULL
(	NULL
HTLV-I	NULL
)	NULL
pX	NULL
mRNA	NULL
in	NULL
infected	NULL
cell	NULL
lines	NULL
and	NULL
in	NULL
primary	NULL
uncultured	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
adult	NULL
T-cell	NULL
leukemia/lymphoma	NULL
and	NULL
healthy	NULL
carriers	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1992	NULL
;	NULL
89:3005-3009	NULL
.	NULL

Ciminale	NULL
V	NULL
,	NULL
Pavlakis	NULL
GN	NULL
,	NULL
Derse	NULL
D	NULL
,	NULL
Cunningham	NULL
CP	NULL
,	NULL
Felber	NULL
BK	NULL
.	NULL

Complex	NULL
splicing	NULL
in	NULL
the	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
(	NULL
HTLV	NULL
)	NULL
family	NULL
of	NULL
retrovi-ruses	NULL
:	NULL
novel	NULL
mRNAs	NULL
and	NULL
proteins	NULL
produced	NULL
by	NULL
HTLV-I	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

1992	NULL
;	NULL
66:1737-1745.	NULL
.	NULL

Franchini	NULL
G.	NULL
Molecular	NULL
mechanisms	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia/lymphotropic	NULL
virus	NULL
type	NULL
|	NULL
infec-tion	NULL
.	NULL

Blood	NULL
.	NULL

1995	NULL
;	NULL
86:3619-3639.	NULL
.	NULL

Koralnik	NULL
1	NULL
,	NULL
Gessain	NULL
A	NULL
,	NULL
Klotman	NULL
ME	NULL
,	NULL
Lo	NULL
Monico	NULL
A	NULL
,	NULL
Berneman	NULL
ZN	NULL
,	NULL
Franchini	NULL
G.	NULL
Protein	NULL
isoforms	NULL
encoded	NULL
by	NULL
the	NULL
pX	NULL
region	NULL
of	NULL
the	NULL
human	NULL
T-cell	NULL
leukemia/lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1992	NULL
;	NULL
89:8813-8817.	NULL
.	NULL

Migone	NULL
TS	NULL
,	NULL
Lin	NULL
JX	NULL
,	NULL
Cereseto	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Constitu-	NULL
tively	NULL
activated	NULL
JAK-STAT	NULL
pathway	NULL
in	NULL
T-cells	NULL
10.	NULL
transformed	NULL
with	NULL
HTLV-I	NULL
.	NULL

Science	NULL
.	NULL

1995	NULL
;	NULL
269:79-81	NULL
.	NULL

..	NULL
Mulloy	NULL
JC	NULL
,	NULL
Migone	NULL
T-S	NULL
,	NULL
Ross	NULL
TM	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Human	NULL
and	NULL
simian	NULL
T-cell	NULL
leukemia	NULL
viruses	NULL
type	NULL
2	NULL
(	NULL
HTLV-2	NULL
and	NULL
STLV-2pan-p	NULL
)	NULL
transform	NULL
T-cells	NULL
independently	NULL
of	NULL
Jak/STAT	NULL
activation	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

1998	NULL
;	NULL
72:4408-4412.	NULL
.	NULL

Xu	NULL
X	NULL
,	NULL
Kang	NULL
SH	NULL
,	NULL
Heidenrich	NULL
O	NULL
,	NULL
Okerholm	NULL
M	NULL
,	NULL
O'Shea	NULL
JJ	NULL
,	NULL
Nerenberg	NULL
MI	NULL
.	NULL

Constitutive	NULL
activation	NULL
of	NULL
different	NULL
Jak	NULL
tyrosine	NULL
kinases	NULL
in	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HTLV-1	NULL
)	NULL
tax	NULL
protein	NULL
or	NULL
vi-rus-transformed	NULL
cells	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
.	NULL

1995	NULL
;	NULL
96	NULL
:	NULL
1548-1555.	NULL
.	NULL

Migone	NULL
TS	NULL
,	NULL
Cacalano	NULL
NA	NULL
,	NULL
Taylor	NULL
N	NULL
,	NULL
Yi	NULL
T	NULL
,	NULL
Wald	NULL
mann	NULL
TA	NULL
,	NULL
Johnston	NULL
JA	NULL
.	NULL

Recruitment	NULL
of	NULL
SH2-con-taining	NULL
protein	NULL
tyrosine	NULL
phosphatase	NULL
SHP-1	NULL
to	NULL
the	NULL
interleukin	NULL
2	NULL
receptor	NULL
;	NULL
loss	NULL
of	NULL
SHP-1	NULL
expression	NULL
in	NULL
human	NULL
T-lymphotropic	NULL
virus	NULL
type	NULL
|-trans-formed	NULL
T	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1998	NULL
;	NULL
95:3845-3850	NULL
.	NULL

Leonard	NULL
WJ	NULL
,	NULL
O'Shea	NULL
JJ	NULL
.	NULL

JAKs	NULL
and	NULL
STATs	NULL
:	NULL
biological	NULL
implications	NULL
.	NULL

Annu	NULL
Rev	NULL
Immunol	NULL
.	NULL

1998	NULL
;	NULL
16	NULL
:	NULL
293-322	NULL
.	NULL

..	NULL
Wattel	NULL
E	NULL
,	NULL
Vartanian	NULL
JP	NULL
,	NULL
Pannetier	NULL
C	NULL
,	NULL
Wain-Hob-	NULL
son	NULL
S.	NULL
Clonal	NULL
expansion	NULL
of	NULL
human	NULL
T-cell	NULL
leuke-	NULL
16.	NULL
mia	NULL
virus	NULL
type	NULL
l-infected	NULL
cells	NULL
in	NULL
asymptomatic	NULL
and	NULL
symptomatic	NULL
carriers	NULL
without	NULL
malignancy	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

1995	NULL
;	NULL
69:2863-2868.	NULL
.	NULL

Koralnik	NULL
IJ	NULL
,	NULL
Fullen	NULL
J	NULL
,	NULL
Franchini	NULL
G.	NULL
The	NULL
p12	NULL
,	NULL
p13	NULL
``	NULL
,	NULL
and	NULL
p30	NULL
``	NULL
proteins	NULL
encoded	NULL
by	NULL
human	NULL
T-cell	NULL
leukemia/lymphotropic	NULL
virus	NULL
type	NULL
|	NULL
open	NULL
reading	NULL
frames	NULL
|	NULL
and	NULL
II	NULL
are	NULL
localized	NULL
in	NULL
three	NULL
different	NULL
cellular	NULL
compartments	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

1993	NULL
;	NULL
67:2360-2366.	NULL
.	NULL

Trovato	NULL
R	NULL
,	NULL
Mulloy	NULL
JC	NULL
,	NULL
Johnson	NULL
JM	NULL
,	NULL
Takemoto	NULL
S	NULL
,	NULL
de	NULL
Oliveira	NULL
MP	NULL
,	NULL
Franchini	NULL
G.	NULL
A	NULL
lysine-to-arginine	NULL
change	NULL
found	NULL
in	NULL
natural	NULL
alleles	NULL
of	NULL
the	NULL
HTLV-I	NULL
p12	NULL
!	NULL

protein	NULL
greatly	NULL
influences	NULL
its	NULL
stability	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

1999	NULL
;	NULL
73:6460-6467	NULL
.	NULL

._	NULL
Franchini	NULL
G	NULL
,	NULL
Mulloy	NULL
JC	NULL
,	NULL
Koralnik	NULL
IJ	NULL
,	NULL
et	NULL
al	NULL
.	NULL

The	NULL
hu-	NULL
man	NULL
T-cell	NULL
leukemia/lymphotropic	NULL
virus	NULL
type	NULL
|	NULL
p12	NULL
!	NULL

protein	NULL
cooperates	NULL
with	NULL
the	NULL
E5	NULL
oncoprotein	NULL
of	NULL
bovine	NULL
papillomavirus	NULL
in	NULL
cell	NULL
transformation	NULL
and	NULL
binds	NULL
the	NULL
16-kilodalton	NULL
subunit	NULL
of	NULL
the	NULL
vacuolar	NULL
H+	NULL
ATPase	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

1993	NULL
;	NULL
67:7701-7704.	NULL
.	NULL

Koralnik	NULL
|	NULL
,	NULL
Lemp	NULL
JF	NULL
Jr	NULL
,	NULL
Gallo	NULL
RC	NULL
,	NULL
Franchini	NULL
G.	NULL
In	NULL
vitro	NULL
infection	NULL
of	NULL
human	NULL
macrophages	NULL
by	NULL
human	NULL
T-cell	NULL
leukemia/lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
(	NULL
HTLV-1	NULL
)	NULL
.	NULL

AIDS	NULL
Res	NULL
Hum	NULL
Retroviruses	NULL
.	NULL

1992	NULL
;	NULL
8:1845-1849	NULL
.	NULL

Dekaban	NULL
GA	NULL
,	NULL
Peters	NULL
AA	NULL
,	NULL
Mulloy	NULL
JC	NULL
,	NULL
et	NULL
al	NULL
.	NULL

The	NULL
BLOOD	NULL
,	NULL
1	NULL
AUGUST	NULL
2001	NULL
«	NULL
VOLUME	NULL
98	NULL
,	NULL
NUMBER	NULL
3	NULL
17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

286	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

HTLV-I	NULL
orf	NULL
|	NULL
protein	NULL
is	NULL
recognized	NULL
by	NULL
serum	NULL
antibodies	NULL
from	NULL
naturally	NULL
infected	NULL
humans	NULL
and	NULL
experimentally	NULL
infected	NULL
rabbits	NULL
.	NULL

Virology	NULL
.	NULL

2000	NULL
;	NULL
274	NULL
:	NULL
86-93	NULL
.	NULL

Pique	NULL
C	NULL
,	NULL
Ureta-Vidal	NULL
A	NULL
,	NULL
Gessain	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Evidence	NULL
for	NULL
the	NULL
chronic	NULL
in	NULL
vivo	NULL
production	NULL
of	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
virus	NULL
type	NULL
|	NULL
Rof	NULL
and	NULL
Tof	NULL
proteins	NULL
from	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
directed	NULL
against	NULL
viral	NULL
peptides	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

2000	NULL
;	NULL
191:567-572	NULL
.	NULL

Collins	NULL
ND	NULL
,	NULL
Newbound	NULL
GC	NULL
,	NULL
Albrecht	NULL
B	NULL
,	NULL
Beard	NULL
JL	NULL
.	NULL

,	NULL
Ratner	NULL
L	NULL
,	NULL
Lairmore	NULL
MD	NULL
.	NULL

Selective	NULL
ablation	NULL
of	NULL
hu-	NULL
man	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
p12	NULL
!	NULL

reduces	NULL
viral	NULL
infectivity	NULL
in	NULL
vivo	NULL
.	NULL

Blood	NULL
.	NULL

1998	NULL
;	NULL
91:4701-4707	NULL
.	NULL

Mulloy	NULL
JC	NULL
,	NULL
Crowley	NULL
RW	NULL
,	NULL
Fullen	NULL
J	NULL
,	NULL
Leonard	NULL
WJ	NULL
,	NULL
Franchini	NULL
G.	NULL
The	NULL
human	NULL
T-cell	NULL
leukemia/lymphotropic	NULL
virus	NULL
type	NULL
|	NULL
p12	NULL
!	NULL

protein	NULL
binds	NULL
the	NULL
interleukin-2	NULL
receptor	NULL
B	NULL
and	NULL
y	NULL
,	NULL
chains	NULL
and	NULL
affects	NULL
their	NULL
expression	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

1996	NULL
;	NULL
70	NULL
:	NULL
3599-3605	NULL
.	NULL

Smith	NULL
KA	NULL
,	NULL
Jacobson	NULL
EL	NULL
,	NULL
Emert	NULL
R	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Restoration	NULL
of	NULL
immunity	NULL
with	NULL
interleukin-2	NULL
therapy	NULL
.	NULL

AIDS	NULL
Read	NULL
.	NULL

1999	NULL
;	NULL
9:563-572	NULL
.	NULL

Bowman	NULL
T	NULL
,	NULL
Garcia	NULL
R	NULL
,	NULL
Turkson	NULL
J	NULL
,	NULL
Jove	NULL
R.	NULL
STATs	NULL
in	NULL
oncogenesis	NULL
.	NULL

Oncogene	NULL
.	NULL

2000	NULL
;	NULL
19:2474-2488	NULL
.	NULL

Takemoto	NULL
S	NULL
,	NULL
Mulloy	NULL
JC	NULL
,	NULL
Cereseto	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Prolit-eration	NULL
of	NULL
adult	NULL
T-cell	NULL
leukemia/lymphoma	NULL
cells	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
constitutive	NULL
activation	NULL
of	NULL
JAK/	NULL
STAT	NULL
proteins	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1997	NULL
;	NULL
94:13897-13902	NULL
.	NULL

Bromberg	NULL
J	NULL
,	NULL
Darnell	NULL
JE	NULL
.	NULL

The	NULL
role	NULL
of	NULL
STATs	NULL
in	NULL
transcriptional	NULL
control	NULL
and	NULL
their	NULL
impact	NULL
on	NULL
cellular	NULL
function	NULL
.	NULL

Oncogene	NULL
.	NULL

2000	NULL
;	NULL
19:2468-2473	NULL
.	NULL

Nakamura	NULL
Y	NULL
,	NULL
Russell	NULL
SM	NULL
,	NULL
Mess	NULL
SA	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Het-erodimerization	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
B-	NULL
and	NULL
y-chain	NULL
cytoplasmic	NULL
domains	NULL
is	NULL
required	NULL
for	NULL
sig-nalling	NULL
.	NULL

Nature	NULL
.	NULL

1994	NULL
;	NULL
369:330-333	NULL
.	NULL

Naldini	NULL
L	NULL
,	NULL
Blomer	NULL
U	NULL
,	NULL
Gallay	NULL
P	NULL
,	NULL
et	NULL
al	NULL
.	NULL

In	NULL
vivo	NULL
gene	NULL
delivery	NULL
and	NULL
stable	NULL
transduction	NULL
of	NULL
nondividing	NULL
cells	NULL
by	NULL
a	NULL
lentiviral	NULL
vector	NULL
.	NULL

Science	NULL
.	NULL

1996	NULL
;	NULL
272	NULL
:	NULL
263-267	NULL
.	NULL

Graham	NULL
FL	NULL
,	NULL
van	NULL
der	NULL
Eb	NULL
AJ	NULL
.	NULL

A	NULL
new	NULL
technique	NULL
for	NULL
the	NULL
assay	NULL
of	NULL
infectivity	NULL
of	NULL
human	NULL
adenovirus	NULL
5	NULL
DNA	NULL
.	NULL

Virology	NULL
.	NULL

1973	NULL
;	NULL
52:456-460	NULL
.	NULL

Zhu	NULL
M-H	NULL
,	NULL
Berry	NULL
JA	NULL
,	NULL
Russell	NULL
SM	NULL
,	NULL
Leonard	NULL
WJ	NULL
.	NULL

Delineation	NULL
of	NULL
the	NULL
regions	NULL
of	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
receptor	NULL
B	NULL
chain	NULL
important	NULL
for	NULL
association	NULL
of	NULL
Jaki	NULL
and	NULL
Jak3	NULL
:	NULL
Jak1	NULL
-independent	NULL
functional	NULL
recruitment	NULL
of	NULL
Jak3	NULL
to	NULL
J	NULL
Biol	NULL
Chem	NULL
.	NULL

1998	NULL
;	NULL
273	NULL
:	NULL
10719-10725	NULL
.	NULL

Yu	NULL
CL	NULL
,	NULL
Burakoff	NULL
SJ	NULL
.	NULL

Involvement	NULL
of	NULL
proteasomes	NULL
in	NULL
regulating	NULL
Jak-STAT	NULL
pathways	NULL
upon	NULL
interleukin-2	NULL
stimulation	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
.	NULL

1997	NULL
;	NULL
272:14017-14020	NULL
.	NULL

Hatakeyama	NULL
M	NULL
,	NULL
Mori	NULL
H	NULL
,	NULL
Doi	NULL
T	NULL
,	NULL
Taniguchi	NULL
T.	NULL
A	NULL
restricted	NULL
cytoplasmic	NULL
region	NULL
of	NULL
IL-2	NULL
receptor	NULL
B	NULL
chain	NULL
is	NULL
essential	NULL
for	NULL
growth	NULL
signal	NULL
transduction	NULL
but	NULL
not	NULL
for	NULL
ligand	NULL
binding	NULL
and	NULL
internalization	NULL
.	NULL

Cell	NULL
.	NULL

1989	NULL
;	NULL
59:837-845	NULL
.	NULL

Scudiero	NULL
DA	NULL
,	NULL
Shoemaker	NULL
RH	NULL
,	NULL
Paull	NULL
KD	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Evaluation	NULL
of	NULL
a	NULL
soluble	NULL
tetrazolium/formazan	NULL
assay	NULL
for	NULL
cell	NULL
growth	NULL
and	NULL
drug	NULL
sensitivity	NULL
in	NULL
culture	NULL
using	NULL
human	NULL
and	NULL
other	NULL
tunor	NULL
cell	NULL
lines	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

1988	NULL
;	NULL
48:4827-4833	NULL
.	NULL

Albrecht	NULL
B	NULL
,	NULL
Collins	NULL
ND	NULL
,	NULL
Burniston	NULL
MT	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Human	NULL
T-lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
open	NULL
reading	NULL
32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45.	NULL
frame	NULL
|	NULL
p12	NULL
(	NULL
1	NULL
)	NULL
is	NULL
required	NULL
for	NULL
efficient	NULL
viral	NULL
infectivity	NULL
in	NULL
primary	NULL
lymphocytes	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

2000	NULL
;	NULL
74:9828-9835	NULL
.	NULL

Li	NULL
HC	NULL
,	NULL
Fujiyoshi	NULL
T	NULL
,	NULL
Lou	NULL
H	NULL
,	NULL
et	NULL
al	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
ancient	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
provirus	NULL
DNA	NULL
in	NULL
an	NULL
Andean	NULL
mummy	NULL
.	NULL

Nat	NULL
Med	NULL
.	NULL

1999	NULL
;	NULL
5:1428-1432	NULL
.	NULL

Mulloy	NULL
JC	NULL
,	NULL
Kislyakova	NULL
T	NULL
,	NULL
Cereseto	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Human	NULL
T-cell	NULL
lymphotropic/eukemia	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
abrogates	NULL
p53-induced	NULL
cell	NULL
cycle	NULL
arrest	NULL
and	NULL
apoptosis	NULL
through	NULL
its	NULL
CREB/ATF	NULL
functional	NULL
domain	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

1998	NULL
;	NULL
72:8852-8860	NULL
.	NULL

Pise-Masison	NULL
CA	NULL
,	NULL
Radonovich	NULL
M	NULL
,	NULL
Sakaguchi	NULL
K	NULL
,	NULL
Appella	NULL
E	NULL
,	NULL
Brady	NULL
JN	NULL
.	NULL

Phosphorylation	NULL
of	NULL
p53	NULL
:	NULL
a	NULL
novel	NULL
pathway	NULL
for	NULL
p53	NULL
inactivation	NULL
in	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
1-transformed	NULL
cells	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

1998	NULL
;	NULL
72:6348-6355	NULL
.	NULL

Pise-Masison	NULL
CA	NULL
,	NULL
Choi	NULL
K-S	NULL
,	NULL
Radonovich	NULL
M	NULL
,	NULL
Ditt-mer	NULL
J	NULL
,	NULL
Kim	NULL
S-J	NULL
,	NULL
Brady	NULL
JN	NULL
.	NULL

Inhibition	NULL
of	NULL
p53	NULL
trans-activation	NULL
function	NULL
by	NULL
the	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
protein	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

1998	NULL
;	NULL
72	NULL
:	NULL
1165-1170	NULL
.	NULL

Franchini	NULL
G	NULL
,	NULL
Cereseto	NULL
A	NULL
,	NULL
Tryniszewska	NULL
E	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Telomerase	NULL
activation	NULL
,	NULL
rearrangement	NULL
,	NULL
and	NULL
inhibition	NULL
of	NULL
cell-cycle	NULL
inhibitors	NULL
in	NULL
human	NULL
T-cells	NULL
immortalized	NULL
or	NULL
transformed	NULL
by	NULL
HTLV-I	NULL
.	NULL

In	NULL
:	NULL
Semmes	NULL
OJ	NULL
,	NULL
Hammarskjold	NULL
M-L	NULL
,	NULL
eds	NULL
.	NULL

Molecular	NULL
Patho-genesis	NULL
of	NULL
HTLV-I	NULL
:	NULL
A	NULL
Current	NULL
Perspective	NULL
.	NULL

Arling-ton	NULL
,	NULL
VA	NULL
:	NULL
ABI	NULL
Professional	NULL
Publications	NULL
;	NULL
1999:59-70	NULL
.	NULL

Low	NULL
KG	NULL
,	NULL
Dorner	NULL
LF	NULL
,	NULL
Fernando	NULL
DB	NULL
,	NULL
Grossman	NULL
J	NULL
,	NULL
Jeang	NULL
K-T	NULL
,	NULL
Comb	NULL
MJ	NULL
.	NULL

Human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
tax	NULL
releases	NULL
cell	NULL
cycle	NULL
arrest	NULL
induced	NULL
by	NULL
p16INK4a	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

1997	NULL
;	NULL
71:1956-1962	NULL
.	NULL

Suzuki	NULL
T	NULL
,	NULL
Kitao	NULL
S	NULL
,	NULL
Matsushime	NULL
H	NULL
,	NULL
Yoshida	NULL
M.	NULL
HTLV-I	NULL
Tax	NULL
protein	NULL
interacts	NULL
with	NULL
cyclin-depen-dent	NULL
kinase	NULL
inhibitor	NULL
p16	NULL
!	NULL
``	NULL

and	NULL
counteracts	NULL
its	NULL
inhibitory	NULL
activity	NULL
towards	NULL
CDK4	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

1996	NULL
;	NULL
15:1607-1614	NULL
.	NULL

Neuveut	NULL
C	NULL
,	NULL
Low	NULL
KG	NULL
,	NULL
Maldarelli	NULL
F	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
Tax	NULL
and	NULL
cell	NULL
cycle	NULL
progression	NULL
:	NULL
role	NULL
of	NULL
cyclin	NULL
D-edk	NULL
and	NULL
p110Rb	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

1998	NULL
;	NULL
18:3620-3632	NULL
.	NULL

Jin	NULL
D-¥	NULL
,	NULL
Spencer	NULL
F	NULL
,	NULL
Jeang	NULL
K-T.	NULL
Human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
oncoprotein	NULL
Tax	NULL
targets	NULL
the	NULL
human	NULL
mitotic	NULL
checkpoint	NULL
protein	NULL
MAD1	NULL
.	NULL

Cell	NULL
.	NULL

1998	NULL
;	NULL
93:1-20	NULL
.	NULL

Nicot	NULL
C	NULL
,	NULL
Mahieux	NULL
R	NULL
,	NULL
Opavsky	NULL
R	NULL
,	NULL
et	NULL
al	NULL
.	NULL

HTLV-I	NULL
Tax	NULL
transrepresses	NULL
the	NULL
human	NULL
c-Myb	NULL
promoter	NULL
independently	NULL
of	NULL
its	NULL
interaction	NULL
with	NULL
CBP	NULL
or	NULL
p300	NULL
.	NULL

Oncogene	NULL
.	NULL

2000	NULL
;	NULL
19:2155-2164	NULL
.	NULL

Nicot	NULL
C	NULL
,	NULL
Opavsky	NULL
R	NULL
,	NULL
Mahieux	NULL
R	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Tax	NULL
oncoprotein	NULL
trans-represses	NULL
the	NULL
endogenous	NULL
B-myb	NULL
promoter	NULL
activity	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

AIDS	NULL
Res	NULL
Hum	NULL
Retroviruses	NULL
.	NULL

2000	NULL
;	NULL
16:1629-1632	NULL
.	NULL

Nicot	NULL
C	NULL
,	NULL
Mahieux	NULL
R	NULL
,	NULL
Takemoto	NULL
S	NULL
,	NULL
Franchini	NULL
G.	NULL
Bcl-X	NULL
;	NULL
is	NULL
up-regulated	NULL
by	NULL
HTLV	NULL
type	NULL
|	NULL
and	NULL
type	NULL
II	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
ex	NULL
vivo	NULL
ATLL	NULL
samples	NULL
.	NULL

Blood	NULL
.	NULL

2000	NULL
;	NULL
96:275-281	NULL
.	NULL

Good	NULL
L	NULL
,	NULL
Maggirwar	NULL
SB	NULL
,	NULL
Harhaj	NULL
EW	NULL
,	NULL
Sun	NULL
S-C.	NULL
Constitutive	NULL
dephosphorylation	NULL
and	NULL
activation	NULL
of	NULL
a	NULL
member	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
NF-AT1	NULL
,	NULL
in	NULL
Tax-expressing	NULL
and	NULL
type	NULL
|	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus-infected	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
.	NULL

1997	NULL
;	NULL
272:1425-1428	NULL
.	NULL

Good	NULL
L	NULL
,	NULL
Maggirwar	NULL
SB	NULL
,	NULL
Sun	NULL
S-C.	NULL
Activation	NULL
of	NULL
the	NULL
46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

HTLV-1	NULL
p12	NULL
!	NULL

ACTIVATES	NULL
STATS	NULL
-	NULL
829	NULL
IL-2	NULL
gene	NULL
promoter	NULL
by	NULL
HTLV-I	NULL
Tax	NULL
involves	NULL
induction	NULL
of	NULL
NF-AT	NULL
complexes	NULL
bound	NULL
to	NULL
the	NULL
CD28-responsive	NULL
element	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

1996	NULL
;	NULL
15:3744-3750	NULL
.	NULL

Ballard	NULL
DW	NULL
,	NULL
Dohnlein	NULL
E	NULL
,	NULL
Lowenthal	NULL
JW	NULL
,	NULL
Wano	NULL
Y	NULL
,	NULL
Franza	NULL
BR	NULL
,	NULL
Greene	NULL
WC	NULL
.	NULL

HTLV-I	NULL
tax	NULL
induces	NULL
cellular	NULL
proteins	NULL
that	NULL
activate	NULL
the	NULL
x	NULL
B	NULL
element	NULL
in	NULL
the	NULL
IL-2	NULL
receptor	NULL
«	NULL
gene	NULL
.	NULL

Science	NULL
.	NULL

1988	NULL
;	NULL
241:1652-1655	NULL
.	NULL

Jacobson	NULL
S	NULL
,	NULL
Shida	NULL
H	NULL
,	NULL
McFarlin	NULL
DE	NULL
,	NULL
Fauci	NULL
AS	NULL
,	NULL
Koenig	NULL
S.	NULL
Circulating	NULL
CD8+	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
specific	NULL
for	NULL
HTLV-I	NULL
pX	NULL
in	NULL
patients	NULL
with	NULL
HTLV-I	NULL
associated	NULL
neurological	NULL
disease	NULL
.	NULL

Nature	NULL
.	NULL

1990	NULL
;	NULL
348:245-248	NULL
.	NULL

Agape	NULL
P	NULL
,	NULL
Copin	NULL
MC	NULL
,	NULL
Cavrois	NULL
M	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Implication	NULL
of	NULL
HTLV-I	NULL
infection	NULL
,	NULL
strongyloidiasis	NULL
,	NULL
and	NULL
P53	NULL
overexpression	NULL
in	NULL
the	NULL
development	NULL
,	NULL
response	NULL
to	NULL
treatment	NULL
,	NULL
and	NULL
evolution	NULL
of	NULL
non-Hodgkin	NULL
's	NULL
lymphomas	NULL
in	NULL
an	NULL
endemic	NULL
area	NULL
(	NULL
Martinique	NULL
,	NULL
French	NULL
West	NULL
Indies	NULL
)	NULL
.	NULL

J	NULL
Acquir	NULL
Immune	NULL
Defic	NULL
Syndr	NULL
Hum	NULL
Retrovirol	NULL
.	NULL

1999	NULL
;	NULL
20:394-402	NULL
.	NULL

Arakaki	NULL
T	NULL
,	NULL
Asato	NULL
R	NULL
,	NULL
Ikeshiro	NULL
T	NULL
,	NULL
Sakiyama	NULL
K	NULL
,	NULL
Iwanaga	NULL
M.	NULL
Is	NULL
the	NULL
prevalence	NULL
of	NULL
HTLV-1	NULL
infection	NULL
higher	NULL
in	NULL
Strongyloides	NULL
carriers	NULL
than	NULL
in	NULL
non-carri-ers	NULL
?	NULL

Trop	NULL
Med	NULL
Parasitol	NULL
.	NULL

1992	NULL
;	NULL
43:199-200	NULL
.	NULL

Arakaki	NULL
T	NULL
,	NULL
Kohakura	NULL
M	NULL
,	NULL
Asato	NULL
R	NULL
,	NULL
Ikeshiro	NULL
T	NULL
,	NULL
Nakamura	NULL
S	NULL
,	NULL
Iwanaga	NULL
M.	NULL
Epidemiological	NULL
aspects	NULL
of	NULL
Strongyloides	NULL
stercoralis	NULL
intection	NULL
in	NULL
Okinawa	NULL
,	NULL
Japan	NULL
.	NULL

J	NULL
Trop	NULL
Med	NULL
Hyg	NULL
.	NULL

1992	NULL
;	NULL
95:210-213	NULL
.	NULL

Atkins	NULL
NS	NULL
,	NULL
Lindo	NULL
JF	NULL
,	NULL
Lee	NULL
MG	NULL
,	NULL
Hanchard	NULL
B	NULL
,	NULL
Robinson	NULL
RD	NULL
,	NULL
Bundy	NULL
DA	NULL
.	NULL

Immunomodulatory	NULL
effects	NULL
of	NULL
concurrent	NULL
HTLV-I	NULL
infection	NULL
in	NULL
strongyloidiasis	NULL
.	NULL

J	NULL
Acquir	NULL
Immune	NULL
Defic	NULL
Syndr	NULL
Hum	NULL
Retrovirol	NULL
.	NULL

1998	NULL
;	NULL
18:188-190	NULL
.	NULL

Lu	NULL
X	NULL
,	NULL
Yu	NULL
H	NULL
,	NULL
Liu	NULL
S	NULL
,	NULL
Brodsky	NULL
F	NULL
,	NULL
Peterlin	NULL
B.	NULL
interactions	NULL
between	NULL
HIV1	NULL
Nef	NULL
and	NULL
vacuolar	NULL
ATPase	NULL
facilitate	NULL
the	NULL
internalization	NULL
of	NULL
CD4	NULL
.	NULL

Immunity	NULL
.	NULL

1998	NULL
;	NULL
8:647-656	NULL
.	NULL

Manninen	NULL
A	NULL
,	NULL
Herma	NULL
Renkema	NULL
G	NULL
,	NULL
Saksela	NULL
K.	NULL
Synergistic	NULL
activation	NULL
of	NULL
NFAT	NULL
by	NULL
HIV-1	NULL
nef	NULL
and	NULL
the	NULL
Ras/MAPK	NULL
pathway	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
.	NULL

2000	NULL
;	NULL
275	NULL
:	NULL
16513-16517	NULL
.	NULL

Schrager	NULL
JA	NULL
,	NULL
Marsh	NULL
JW	NULL
.	NULL

HIV-1	NULL
Nef	NULL
increases	NULL
T	NULL
cell	NULL
activation	NULL
in	NULL
a	NULL
stimulus-dependent	NULL
manner	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

1999	NULL
;	NULL
96:8167-8172	NULL
.	NULL

Wang	NULL
JK	NULL
,	NULL
Kiyokawa	NULL
E	NULL
,	NULL
Verdin	NULL
E	NULL
,	NULL
Trono	NULL
D.	NULL
The	NULL
Nef	NULL
protein	NULL
of	NULL
HIV-1	NULL
associates	NULL
with	NULL
rafts	NULL
and	NULL
primes	NULL
T	NULL
cells	NULL
for	NULL
activation	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
U	NULL
S	NULL
A	NULL
.	NULL

2000	NULL
;	NULL
97:394-399	NULL
.	NULL

Derse	NULL
D	NULL
,	NULL
Mikovits	NULL
J	NULL
,	NULL
Ruscetti	NULL
F.	NULL
X-	NULL
!	NULL

and	NULL
X-ll	NULL
open	NULL
reading	NULL
frames	NULL
of	NULL
HTLV-I	NULL
are	NULL
not	NULL
required	NULL
for	NULL
virus	NULL
replication	NULL
or	NULL
for	NULL
immortalization	NULL
of	NULL
primary	NULL
T-cells	NULL
in	NULL
vitro	NULL
.	NULL

Virology	NULL
.	NULL

1997	NULL
;	NULL
237:123-128	NULL
.	NULL

Robek	NULL
MD	NULL
,	NULL
Wong	NULL
F-H	NULL
,	NULL
Ratner	NULL
L.	NULL
Human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
pX-|	NULL
and	NULL
pX-II	NULL
open	NULL
reading	NULL
frames	NULL
are	NULL
dispensable	NULL
for	NULL
the	NULL
immortalization	NULL
of	NULL
primary	NULL
lymphocytes	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

1998	NULL
;	NULL
72:4458-4462	NULL
.	NULL

Johnson	NULL
JM	NULL
,	NULL
Nicot	NULL
C	NULL
,	NULL
Fullen	NULL
J	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Free	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
|	NULL
heavy	NULL
chain	NULL
is	NULL
preferentially	NULL
targeted	NULL
for	NULL
degradation	NULL
by	NULL
human	NULL
T-cell	NULL
leukemia/lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
p12	NULL
!	NULL

protein	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

In	NULL
press	NULL
.	NULL

Waldmann	NULL
TA	NULL
,	NULL
Dubois	NULL
S	NULL
,	NULL
Tagaya	NULL
Y	NULL
.	NULL

Contrasting	NULL
roles	NULL
of	NULL
IL-2	NULL
and	NULL
IL-15	NULL
in	NULL
the	NULL
life	NULL
and	NULL
death	NULL
of	NULL
lym-phocytes	NULL
:	NULL
implications	NULL
for	NULL
immunotherapy	NULL
.	NULL

Immunity	NULL
.	NULL

2001	NULL
;	NULL
14:105-110	NULL
.	NULL

From	NULL
www	NULL
.	NULL

bloodjournal.org	NULL
by	NULL
guest	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

For	NULL
personal	NULL
use	NULL
only	NULL
.	NULL

®	NULL
2001	NULL
98	NULL
:	NULL
823-829	NULL
doi:10.1182/blood.V98.3.823	NULL
HTLV-1	NULL
p1	NULL
al	NULL
protein	NULL
enhances	NULL
STATS	NULL
activation	NULL
and	NULL
decreases	NULL
the	NULL
interleukin-2	NULL
requirement	NULL
for	NULL
proliferation	NULL
of	NULL
primary	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
TY	NULL
O	NULL
0C	NULL
,	NULL
A	NULL
f	NULL
ghURIC	NULL
ANA	NULL
a	NULL
'	NULL
%	NULL
:	NULL
r	NULL
)	NULL
...	NULL
3\	NULL
®	NULL
``	NULL
Pion	NULL
(	NULL
@	NULL
0	NULL
Christophe	NULL
Nicot	NULL
,	NULL
James	NULL
C.	NULL
Mulloy	NULL
,	NULL
Maria	NULL
G.	NULL
Ferrari	NULL
,	NULL
Julie	NULL
M.	NULL
Johnson	NULL
,	NULL
Kaisong	NULL
Fu	NULL
,	NULL
Risaku	NULL
Fukumoto	NULL
,	NULL
Raffaella	NULL
Trovato	NULL
,	NULL
Jake	NULL
Fullen	NULL
,	NULL
Warren	NULL
J.	NULL
Leonard	NULL
and	NULL
Genoveffa	NULL
Franchini	NULL
Updated	NULL
information	NULL
and	NULL
services	NULL
can	NULL
be	NULL
found	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/content/98/3/823.full.html	NULL
Articles	NULL
on	NULL
similar	NULL
topics	NULL
can	NULL
be	NULL
found	NULL
in	NULL
the	NULL
following	NULL
Blood	NULL
collections	NULL
Neoplasia	NULL
(	NULL
4182	NULL
articles	NULL
)	NULL
Signal	NULL
Transduction	NULL
(	NULL
1930	NULL
articles	NULL
)	NULL
Information	NULL
about	NULL
reproducing	NULL
this	NULL
article	NULL
in	NULL
parts	NULL
or	NULL
in	NULL
its	NULL
entirety	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
requests	NULL
Information	NULL
about	NULL
ordering	NULL
reprints	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/misc/rights.xhtml	NULL
#	NULL
reprints	NULL
Information	NULL
about	NULL
subscriptions	NULL
and	NULL
ASH	NULL
membership	NULL
may	NULL
be	NULL
found	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.bloodjournal.org/site/subscriptions/index.xhtml	NULL
Blood	NULL
(	NULL
print	NULL
ISSN	NULL
0006-4971	NULL
,	NULL
online	NULL
ISSN	NULL
1528-0020	NULL
)	NULL
,	NULL
is	NULL
published	NULL
weekly	NULL
by	NULL
the	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
,	NULL
2021	NULL
L	NULL
St	NULL
,	NULL
NW	NULL
,	NULL
Suite	NULL
900	NULL
,	NULL
Washington	NULL
DC	NULL
20036	NULL
.	NULL

Copyright	NULL
2011	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
of	NULL
Hematology	NULL
;	NULL
all	NULL
rights	NULL
reserved	NULL
.	NULL

